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INTRODUCTION
HIPPOCRATES, ROGERIUS, PARACELSUS, MANARDI, AMATUS LUSITANUS, 
SENNERT etc.  are  some of  the  early  renowned Physicians  who have  described "LUPUS" 
which  is  derived  from  the  Latin  word  which  means  "WOLF"1 depicting  its  nature  of 
destruction. The ulcerated skin lesions typical of this disease signify this feature as it "bites,  
eats away and destroys".
Lupus erythematosus (LE) was identified only as a cutaneous disease, until a century 
ago when emphasis was transferred from the integument to include visceral manifestations. At 
the beginning of this century blood vessels and connective tissues distributed throughout the 
body came to be implicated in the pathogenesis, which lead  to the concept of  "multisystem 
malady”.2 In 1942, KLEMPERER et al 3 were struck by the many, morphological features that 
were common to diseases as distinct as Lupus erythematosus, Scleroderma, Dermatomyositis, 
Rheumatoid Arthritis, Acute Rheumatic Fever and Poly Arteritis Nodosa and classified them as 
"Collagen disease"  or  "Collagenosis". The discovery of auto antibodies to various cellular 
components  of  different  tissue  in  these  diseases  has  of  late  given place  to  the  concept  of 
"autoimmune diseases".
REVIEW OF LITERATURE
HISTORICAL BACKGROUND:
In 1826 RAYER1 described lupus erythematosus (LE) as "Flexus Sebaceui"; in 1828 
BIETT4 described the condition as "Erythema centrifuge". In 1845 HEBRA1 described it as 
"Seborrhea congestiva" in which the term "butterfly rash” was used for the first time. In 1851, 
CAZENAVE5  introduced  the  term  "lupus  erythematoides"  meaning  red  wolf,  in  order  to 
distinguish this disease from lupus vulgaris. KAPOSI4 differentiated LE into two forms namely 
the discoid form and lupus erythematosus disseminatus.
KAPOSI4 was the first to describe the systemic manifestation of LE (1872). WILLIAM 
OSLER1 in 1903 discussed the significance of systemic manifestations and its relationships to 
the cutaneous lesions.
In 1925 DROCQ6 classified lupus erythematosus (LE) into 3 major categories. In 1934 
O’LEARY6 classified LE into chronic discoid, sub acute disseminate and acute disseminate 
types. The discovery “LE cell phenomenon" in 1948 by HARGRAVES et al1 paved  way to the 
subsequent discoveries of various autoantibodies. The finding of immunoglobulin deposition at 
the DEJ of LE lesions by BURNHAM et al7 in 1963 further strengthened autoimmune etiology. 
In  1971,  COHEN  and  CANOSO8 proposed  the  American  Rheumatic  Association  (ARA) 
criteria for the classification of systemic lupus erythematosus (SLE), which following criticism 
was revised in 1982 by TAR EM et al.9    In 1994 CASCIOLA ROSEN et al first demonstrated 
autoantigens that  are targeted in SLE. WORTH et al  demonstrated presence of 30SA TNF 
promoter polymorphism in SLE.
DEFINITION: 
LE is  a  systemic  autoimmune  disorder  associated  with  polyclonal  B-cell  activation, 
thought  to  result  from interplay  of  genetic,  environment  and  hormonal  elements.  LE  is  a 
spectrum ranging on one end from DLE to SLE on the other end. The term SLE has been used 
in the past synonymously with LE to all patients suffering from this autoimmune disorder. But 
in our discussion SLE will be used to refer only to the patient with systemic manifestations.
AETIOLOGY AND PATHOGENESIS:
The regular manifestations of specific DLE lesions in systemic lupus erythematosus, 
common  histological  and  laboratory  abnormalities,  immunoglobulin  depositions  in  the 
involved skin, the transition of discoid lupus erythematosus to systemic lupus erythematosus, 
etc.10-13 have lead  to the concept that DLE and SLE have common pathogenetic mechanisms in 
which  discoid  lupus  erythematosus  (DLE)  represents  one  polar  expression  with  minimal 
immunological alteration and the systemic lupus erythematosus on the other end with maximal 
immunological alterations.11,12
The current  concepts  suggest  that  this  is  a  multifactorial  disorder  in  which  there  is 
profound disturbance of immune mechanism provoked by constitutional  and environmental 
factors.
I. CONSTITUTIONAL FACTORS:
GENETIC    PREDISPOSITION  :   A  genetic  role  is  suggested  by  the  following 
observations; 1)Familial incidence (5% in the first degree relatives) 14 , 2) Concordance rate in 
identical twins is 65% , 3)The higher incidence of other autoimmune diseases in the patients 
and among family members,16  4) Increased association of HLA B8, B7 and DR3 in idiopathic 
type 17 and increased HLA DR6Y in drug induced lupus erythematosus, 5)The occurrence of 
linkage / disequilibrium among individual alleles at neighboring loci in some which is referred 
as “persistent haplotype” 6) Increased allele of TNF Alfa, IL-I, HSP 70-2 polymorphism and 
decreased  FC receptors, increases the risk of lupus18.
AGE, SEX AND HORMONAL FACTORS:  13 There is an increased oestrogen levels as there is an 
abnormal oestrogen metabolism in patients with SLE, this leads to increased number of self 
reactive lymphocytes and increased number of B cells which has high affinity of recognizing 
self DNA. This observation has a bearing on the propensity for females to develop systemic 
lupus erythematosus and the higher incidence between menarche and menopause and during 
the 3rd trimester of pregnancy, when the circulating oestrogen levels are  high.22 Women in 
childbearing age have 15 times more preponderance for SLE than men.21 Female patients with 
DLE have noted exacerbation of the lesions during the premenstrual and menstrual periods.13 
Prolactin is immunogenic and is associated with high Anti DNA levels.
II. ENVIRONMENTAL FACTORS:
              Environmental factors like viruses, drugs, UV light, trauma by interfering with the 
immune mechanism can precipitate or exacerbate SLE.
VIRUSES:  The  demonstration  of  Paramyxovirus  like  cytoplasmic  tubular  structure  in 
glomerular capillaries23 and endothelial cells of dermal blood vessels by Ken Hashimoto et al24 
suggested a possible viral aetiology. The pathogenesis behind proposed viral etiology include; 
1)  Virus  infected  cells  while  getting  apoptised,  express  their  Ro/SSA and related  antigens 
towards  the surface25.  2)  An alteration of  class  II  proteins by viral  antigens,  may result  in 
preferential activation by altered self MHC class II reactive cells26. 3) By altering MHC class II 
expression there is also a molecular mimicry by viruses and auto antibodies are produced27. 
Other corroborative findings include precipitation or exacerbation of the disease following viral 
infection,  and  increased  titres  of  antibodies  against  various  viruses  like  REO viral  RNA, 
measles,  rubella,  EBV,  parainfluenza  type  1  &  2  are  seen  during  periods  of  disease 
exaggeration28,29.
DRUGS:  A number of drugs have been incriminated either to produce or unmask LE. These 
are listed in Table-1. Hydralazine induced SLE is dose dependent, dosage <50mg/day does not 
induce SLE, likewise minocyclin >100 mg/day, needs 2 years of therapy to induce SLE. 
Table -1
DRUGS INDUCING SLE LIKE SYNDROME
NO TYPE OF DRUGS NAME OF THE DRUG
1. Cardio vascular Procainamide, quinidine
2. Antimicrobial INH, penicillins, sulphonamides, griesofulvin, streptomycin, tetracyclins, nitrofurantoin
3. Antihypertensives Hydralazine, methyldopa, reserpine, atenolol, captopril, labetalol
4. Antithyroid Propylthiouracil
5. Psychotropic Chlorpromazine, lithium
6. Antiepileptic Phenytoin, sodium valproate, ethosuximide, carbamazepine, clobazam
7. Miscellaneous d-penicillamine, phenylbutazone, gold salts, allopurinol, PAS,ibuprofen,OCP’s
            Possible mechanisms hypothesized  are:30  1) Structural similarity of the drug to the 
purine base of DNA, with subsequent cross-reactivity in the induction of antibody production 
to DNA, 2) Interaction of drugs with nuclear antigens expressing a new determinant to evoke T 
lymphocytes help B lymphocytes in producing antibodies,  3)Inhibition of T suppressor cell 
activity,  4)  By genetic  predisposition through an immune response gene and through slow 
acetylation,  5) Drugs may induce T-cell DNA hypomethylation,   may cause increased auto 
reactivity of lymphocytes, 6)increased keratinocyte apoptosis, expose intracellular peptides on 
epidermal surface, enhances pro inflammatory cytokines like IFN alfa and TNF alfa30,31.
UV LIGHT:    Incidence of photosensitivity among SLE patients ranges from 32 to 37%13, in 
patients with DLE from 5 to 40%13 and in patients with sub acute cutaneous LE upto 50%11, 31. It 
has been claimed that there is increased activity of the systemic disease with sun exposure and  
the degree of increased activity is related to the duration of sun exposure.13  Kesten proposed 
that the local reaction to UV injury represents an isomorphic or koebner Phenomenon.25 DLE 
lesions in patients with SLE have been explained to be the result of excessive damage induced 
by sister chromatid inducing agents, the action of which is increased by exposure to near UV 
light. Recent studies using monochromatic sources have confirmed that the photo reactivity lies 
within the sunburn range (UVB). 13
 Pathogenesis  stated  behind  UV  light  includes;  1)  UV  light  causes  apoptosis  of 
keratinocytes,  which  in  turn  makes  previously  cryptic  peptides  available  for  immune 
surveillance leading to self  immunity and loss of  tolerance,  2)  UVB displaces intracellular 
Ro/SSA, LA/SSB, Calreticulin to their cell surfaces, 3) UVB induces release of CCL-27, a 
chemokine,  activates autoreactive T Cells, IFN alfa and dendritic cells leading on  to  alteration 
of   DNA, 4)  UV light  affects  immunoregulatory cells  which normally help in suppressing 
abnormal cutaneous inflammation27,28,16,.
OTHER  FACTORS: Hemolytic  anaemia  with  increased  anti  dsDNA antibodies  has  been 
documented following the ingestion of sprouts, seeds and dietary supplements containing L-
canavanin. Heavy metals like cadmium, mercury, gold, silica, trichlorethylene has also been 
associated with SLE. Lipogenic aromatic amines present in tobacco can induce SLE27,28. Lodin 
reported  DLE  following  trauma  (Koebner  phenomenon)  that  included  chemical  burns, 
diathermy, scars of herpes zoster and exposure to X-rays. 
III. IMMUNOLOGICAL FACTORS:
Complex interaction between various cells like B and T lymphocytes,  dentritic cells, 
complements defects, apoptotic abnormalities, receptor defects, and aberration in chemokine 
secretion leads to autoimmunity.
T  LYMPHOCYTE:   It  is  postulated  that  in  LE, varying  degree  of  impairment  of  the 
suppressor T lymphocytes occur, leading to defect in tolerance to self antigen and over activity  
of  B lymphocyte,  followed by the  production of  antibodies  to  a  wide variety  of  antigens, 
preferably to nuclear proteins. CTL cell has role both in induction and expansion phases by its 
increased number and surface DR antigens23,32. 
B LYMPHOCYTE:  B Cells are involved in expansion phase of pathogenesis. Production of 
auto antibodies against nuclear antigens and immune complexes is the hallmark of SLE, which 
may causes tissue damage by causing direct cell death, cellular activation, opsonization and 
blocking  of  target  molecule  function.  The  excess  B  cell  is  hypothesized  to  result  from; 
1)Primary  B  cell  defect,  2)excess  helper  T  Cell  function,  3)increased  polyclonal  B  cell 
activation and 4)  genes for  high responsiveness to  certain auto antigens or  antigens  which 
cross-react with auto antigens. RES is less efficient in clearing circulating immune complexes, 
which accounts for the widespread tissue injury27,28,32,33.
DEFECTIVE  APOPTOSIS:  In  SLE  apoptosis  of  peripheral  blood  mononuclear  cells  is 
increased and defective. Normally apoptotic cells remain intact,  but in SLE apoptotic cells 
dissolute and release nucleoprotein there by exposing the antigen. The above factor also adds 
up to inherited defect of apoptotic body clearance.34
IDIOTYPE AND ANTI IDIOTYPE ANTIBODY: Idiotype is an antigenic determinant present 
on the variable region of an antibody formation. Antibodies are produced against this idiotype. 
So there is dysregulation of production of immunoglobulins bearing these idiotypes35.
COMPLEMENT DEFECTS:36  There is both inherited and acquired complement deficiency are 
associated with disease. Normally complement binds to apoptotic cells which are then disposed 
by house keeping macrophages but when complement proteins are deficient there is a defective 
clearing of apoptotic cells.  Complement deficiency also produce LE, probably by impaired 
viral  neutralization  and  linkage  of  gene  foci  controlling  complement  synthesis  with  those 
controlling the immune response.36
ROLE OF DENDRITIC CELLS AND IFN ALFA:   Immature dendritic cells normally perform 
a watch dog role by capturing self antigen and keep self antigen in check. In SLE there is more 
plasmacytoid maturation of DC’s via IFN stimulation. These mature DC’s unlike immature 
DC’s present antigen to auto reactive T-cells, there by producing antibodies37.
TOLL LIKE RECEPTORS:  Circutating  DNA /  Anti  DNA complex trigger  TLR signaling 
which induces proliferation of auto reactive B-Cells, IFN secretion from DC’s30,31,18.
TNF:  TNF alfa secreted in response to UVR induce HLA – DR expression, stimulate NF 
Kappa which upregulates proinflammatory cytokines and adhesion molecules30,18.
 Other  corroborative  finding include the  following:   Detection of  circulating immune 
complexes,36 the  deposition  of  immunoglobulin  and  complement  in  different  tissues  like 
kidney, skin etc.,10 the pattern of disease expressivity correlating with the detection of specific 
autoantibodies,  lupus  like  rash  in  graft  versus  host  disease,11 lymphopenia,25 positive 
intradermal  test  on  patients  with  autologus  WBC,  marked  depression  or  absence  of  skin 
reactivity to all test antigens and finally, failure of sensitization to DNCB by majority of the 
patients with SLE.
The immunological aberration increases, as the spectrum moves from DLE to SLE. The 
possible explanation would be the presence of isolated cellmediated autoimmunity in DLE, 
without producing immune complexes. But, in patients with SLE, antigen antibody complexes 
may be the reason for multi organ involvement. However, it is the dichotomy in T suppressor 
cells control over the B-lymphocyte that could best explain the polar expression, though the 
exact pathogenic38  mechanism not known. The various auto antibodies identified are shown in 
the Table-2, and the various immunological abnormalities are enlisted in the Table-3. 
Table-2
I. ANTIBODIES TO DNA AND HISTONES
A. ANTIBODY REACTIVE WITH DOUBLE STRANDED DNA 
ONLY (dsDNA)
B. AGAINST ds AND ss DNA – 60 TO 70% OF PATIENTS WITH SLE
C. AGAINST ss DNA ONLY
D. AGAINST HISTONES (H, AH2A, H2B, H3 AND H4) -DRUG 
INDUCED LE (95-100%),        SLE 30%
II ANTIBODIES TO NON-HISTONE NUCLEAR PROTEINS AND 
RNA PROTEINS
Sm ANTIGEN – SLE IN 30 TO 40% - MARKER ANTIBODY
NUCLEAR RNP (N RNP) – SLE 30 TO 40%
SSA/RO ANTIGEN – SLE 30-40%
SSB/LA ANTIGEN – SLE 10-15%
PROLIFERATING CELL NUCLEAR ANTIGEN (PCNA) – SLE 
5% - 10%
III KU – SLE/PM/SCLERODERMA – OVERLAP SYNDROME
ANTIBODIES TO NUCLEOLAR ANTIGEN
Table-3
IMMUNOLOGICAL   ABNORMALITIES  IN  SLE
ANTI DNA HISTONE ANTIBODY (LE FACTOR)
ANTI DNA ANTIBODY – SS AND DS
ANTI RNA & ANTI SM
CRYOGLOBULIN
COOMBS ANTIBODY
PLATELET, LEUCOCYTE   ANTIBODY,
ORGAN SPECIFIC ANTIBODY (THYROID…ETC)
ANTIBODY TO CLOTTING FACTOR
BIOLOGICAL FALSE POSITIVITY
INCREASED TITRE OF VIRAL ANTIBODY
SERUM COMPLEMENT DEFICIENCY
DEFECTS IN CELLULAR IMMUNITY 
CLASSIFICATION:
The classifications of LE by Brocq in 1925, O'Leary' in 1934, Urbach and Thomas in 
1939 and Wilson and Jordon4 in 1950 can at best be considered as anecdotal importance, since 
there  were  lacunae  in  the  clinical  and  histopathological  correlations.  The  exercise  of 
classification is further complicated by the fact that visceral involvement may or may not be 
accompanied  by  skin  changes.  Based entirely  upon "clinical  and specific  histopathological 
findings”  of  LE, Gilliam et al11 classified cutaneous lesions of LE into,1) LE specific (or) 
cutaneous Lupus Erythematosus (CLE) showing specific histopathological findings and 2) LE 
non specific  skin lesions in which histopathology is not diagnostic of LE. (Table-4) 
Table -4
I. CUTANEOUS LUPUS ERYTHEMATOSUS (LE SPECIFIC SKIN LESIONS)
A. CHRONIC CUTANEOUS LUPUS ERYTHEMATOSUS : (CCLE)
1. LOCALISED DISCOID LUPUS ERYTHEMATOSUS (LDLE) 
(LESIONS ARE CONFINED TO HEAD AND NECK)
2. GENERALISED OR DISSEMINATED DISCOID LUPUS 
ERYTHEMATOSUS (DDLE) –(LESIONS ARE PRESENT ABOVE 
AND BELOW THE NECK)
3. HYPERTROPHIC OR VERRUCOUS DISCOID LUPUS 
ERYTHEMATOSUS 
4. LUPUS ERYTHEMATOSUS PROFUNDUS (LUPUS 
ERYTHEMATOSUS PANNICULITIS)
B SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS (SCLE) 
1. PAPULOSQUAMOUS (PSORIASIFORM) SCLE
2. ANNULAR – POLYCYCLIC (OCCASIONALLY VESICULAR) SCLE
C. ACUTE CUTANEOUS LUPUS ERYTHEMATOSUS (ACLE) 
1. FACIAL (MALAR) ERYTHEMA
2. WIDESPREAD ERYTHEMA OF FACE. SCALP, NECK, UPPER 
CHEST, SHOULDERS, EXTENSOR SURFACES OF ARMS AND 
BACK OF HANDS
3. BULLOUS OR TEN LIKE ACLE 
II. NON SPECIFIC BUT DISEASE RELATED SKIN LESIONS IN 
PATIENTS WITH LUPUS ERYTHEMATOSUS
A. VASCULAR LESIONS
1. TELANGIECTATIC LESIONS (45-65%)
2. DERMAL VASCULITIS (10-20%)
3. THROMBOPHLEBITIS (15-20%)
4. RAYNAUD’S PHENOMENON (15-20%)
5. LIVEDO RETICULARIS (10%)
6. CHRONIC ULCERS (2-8%)
7. RHEUMATOID NODULES (5-10%)
8 PERIPHERAL GANGRENE (LESS THAN 5%)
9. DEGOS LIKE DERMAL INFARCTS OR ATROPHIE BLANCHE 
(LESS THAN 5%)
B ALOPECIA (40-60%)
1. FRONTAL (“LUPUS HAIR”)
2. DIFFUSE (NON SCARRING)
C MUCOUS MEMBRANE LESIONS (7%)
D PIGMENTARY ABNORMALITIES (10%)
E. SCLERODACTYLY (10%)
F CALCINOAIS CUTIS (RARE)
G URTICARIA (7 – 14%)
H BULLOUS LESIONS (LESS THAN 5%)
This  classification  is  again  incomplete  as  it  does  not  encompass  other  variants  of 
cutaneous LE namely, chilblain lupus,10 LE telangiectoides,10 LE profundus et hypertrophicus,10 
LE tumidus,39 and  LE/LP overlap syndrome.
On  the  other  hand,  Baeur  and  Orfanos  preferred  to  use  the  general  term     "LE 
syndrome" which comprised all types of LE disease and regarded the individual clinical picture 
as  LE  subsets.  In  their  classification,  classical  LE  subsets  included  the  chronic  DLE,  the 
disseminated LE and systemic lupus erythematosus (SLE). Among the rare LE subsets few 
were bullous LE, LE profundus, Mixed Connective Tissue Disease, Rowell syndrome, Drug 
induced LE, Urticarial vasculitic LE, and ANA negative LE39 were recently recorded in the 
literature.
CRITERIA FOR THE CLASSIFICATION OF SLE:
In 1964, Ropes40 proposed the following criteria;
1) A cutaneous eruption consistent with LE. 2) Renal involvement. 3) Serositis and  4) 
Joint involvement.
The presence of 3 of the above mentioned 4 manifestations were considered for the 
classification of SLE. The diagnosis of which however required confirmatory laboratory tests.
In 1971, American Rheumatism Association8 proposed the preliminary criteria for the 
classification of SLE, which, after criticism was revised in 1982 by Tan Em et al9 (Table-5). 
Among the 6 cutaneous criteria initially said, Malar flush, discoid rash, photosensitivity and 
oral ulcers  were retained and the Raynaud's  phenomenon and alopecia were excluded.  The 
revised criteria, however, was also subjected to criticism. (Table 5)       
Table – 5
1982 REVISED CRITERIA FOR CLASSIFICATION OF SLE
1. MALAR RASH: Fixed erythema, flat or raised over the malar eminences 
tending to spare the naso labial fold.
2. DISCOID RASH: Erythematous raised patches with adherent keratotic 
scaling  and  follicular  plugging;  atrophic  scarring  may  occur  in  older 
lesions
3 PHOTOSENSITIVITY: Rash as a result of unusual reaction to sunlight 
by history or physician observation.
4 ORAL ULCERS: Oral or nasopharyngeal ulcerations, usually pain less
5 ARTHRITIS: Non  erosive  involving  2  or  more  peripheral  joints 
characterised by tenderness, swelling or effusion.
6 SEROSITIS: (A) Pleuritis:  Convincing history of pleuritic pain or rub 
heard  by  a  physician  or  evidence  of  pleural  effusion  or 
(B). Pericarditis: Documented by ECG or rub or evidence of pericardial 
effusion.
7 RENAL DISORDER: (A) Persistent proteinuria more than 5g per day or 
more than 3+ if quantitation not performed or (B) Cellular casts – may be 
RBC’s, Hb, granular, tubular or mixed.
8 NEUROLOGICAL DISORDERS : (A)  Seizures  :  In  the  absence  of 
offending drugs or known metabolic derangements  or (B) Psychosis
9 HEMATOLOGICAL  DISORDER :  (A)  Hemolytic  anemia  with 
reticulocytosis  (B)  Leukopenia < 4000/cu mm on 2 or more occasions 
or (C)  lymphopenia < 1500 / cu mm on 2 or more occasions or  (D) 
Thrombocytopenia <1,00,000/cu mm in the absence of offending drugs
10 IMMUNOLOGICAL DISORDER : (A) Positive  LE cell  or   (B) Anti 
DNA antibody in abnormal titre  or (C) presence of anti Sm anti body or 
(D) False positive VDRL for atleast 6 months and confirmed by TPI or 
FTA-ABS  
11 Abnormal ANA by immunoflouresence in the absence of drugs
For the purpose of identifying in clinical studies a person shall be said to have SLE, is 
any four or more of the 11 criteria are present serially or simultaneously, during any interval of 
observation.
INCIDENCE:
SLE is not a rare disease, but neither is it a common one. The average annual incidence 
of SLE has been estimated to be 27.5 per million population for white females and 75.4 per 
million  for  black  females.13 SCLE represents  9% of  all  cases  of  cutaneous LE12 and  DLE 
represents the commonest among the cutaneous LE.42,46 Other variants of cutaneous LE seems 
to be extremely rare. 43,44,45,46
AGE INCIDENCE: 
Average age of onset is between the 2nd and 5th decade,10,13 the peak incidence being 
between 3rd and 4th decade in DLE,10,13 It occurs rarely in children47,48, on the other extreme, 
DLE has also started at 83 years of age.10 In the Indian study by Pandh et al49 the majority of 
the patients with DLE were in the age group 21 to 40 years. 
SEX INCIDENCE: 
Females  are  predominantly  affected  and  the  female  to  male  ratio  increases  as  the 
spectrum moves from DLE to SLE. 10,13,25 In DLE the ratio ranges from 1.2:1 in the localised 
type49 upto 3.8:1 in the disseminated type.50 70% of the patients are females in the SCLE type31 
and  the  ratio  in  ACLE  ranges  from  9:110,13 upto  15:1  in  the  childbearing  age  group. 21
                    RACE:  
SLE  is  three  times  more  common  in  whites  than  blacks.  Blacks  with  SLE  more 
commonly have Sm and RNP antibodies, DLE lesions, Serositis and internal organ damage. 
SYMPTOMS:
 Patients with DLE are often asymptomatic, but for the most common symptom cum 
precipitating  factor  is  photosensitivity.  The  early  papular  lesion  of  DLE may  however  be 
slightly pruritic,13 and intolerable itching is a symptom peculiar to scalp involvement.51,52 Pain 
on scratching in lesions of DLE has been explained by the carpet tack phenomenon.  53 Pain is 
also  present  in  some  patients  with  LE/LP overlap  syndrome46 and  LEP.  Other  symptoms 
include symptoms of associated cutaneous and systemic lesions. 10
DISTRIBUTION OF THE LESIONS:
The  classical  cutaneous  LE  lesions  predominantly  involve  the  face  and  other  sun 
exposed  areas  of  the  body.10,13 The  DLE  lesions  may  be  solitary,  multiple,  localised  or 
disseminated.10,13 The  localised  type11,53,54 is  confined  to  the  head  and  neck  and  the  sites 
commonly affected are malar area, nose, forehead, ears, scalp and external auditory canals. 
SCLE is  usually  widespread and commonly  involves  the  shoulder,  extensor  surface  of  the 
upper extremities, upper chest, upper back and neck but lesions are rarely seen below the waist.  
13,31ACLE may manifest as malar erythema of the face or as generalised morbilliform eruption. 
13,54Hypertrophic  lesions  mainly  manifest  on  the  upper  extremities.  45 LEP predominantly 
involve the face, abdomen, buttocks, upper arm, thighs and breast. 10,56 LE/LP overlap syndrome 
predominantly  involve  the  acral  areas  palms,  soles,  face  and less  commonly  the  trunk.37,57 
Chilblain lupus predominantly involve the digits, calves and heels.
MORPHOLOGY AND COURSE:
DISCOID LUPUS ERYTHEMATOSUS (DLE): 10-13 Starts as an erythematous papule or scaly 
patch and on evolution is characterised by well demarcated erythematous scaly, disc shaped or 
irregular plaque with follicular dilatation and keratotic plugging. When the plug comes out, the 
prickly under surface resembles "Carpet tacks" or "Cats tongue", which is very characteristic of 
DLE.52 There is an active infiltrated margin with peripheral hyperpigmentation. The lesions 
have a tendency to spread peripherally and the central area heals with hyper, hypo or more 
commonly  depigmentation,  telangiectasia,  and  atrophy.  Scarring  with  depigmentation  is  a 
characteristic feature of DLE and it persists indefinitely. Size varies and lesions may remain 
active for months or years together. Scarring of the concha of the ear as a sign of DLE has been  
stressed by Rebra58 and SAM Shuster. 57,58,59 DLE lesions that occur only on the head and (or) 
neck are referred to as localized DLE whereas DLE occurring both above and below the neck 
are referred to as generalized DLE. Various other types of localized DLE includes, patch, warty, 
non itchy hyperkeratotic,  papulonodular lesions,  annular lesions,  acneiform lesions,  rosacea 
like.  Likewise,  morphological  types  of  disseminated  DLE  include  annular  variant,  lupus 
erythematosus gyratus repens, bullous lesions, linear lesions, arteritic lesions.
Oral mucosal involvement has been reported to occur in 3% to 25% of DLE patients,19,60 
while other mucosa like conjuctival, nasal, vulval, perianal are rarely involved. The sites of 
predilection within the mouth are buccal mucosa and the palate but the gingiva may also be 
involved. The lesions of localised LE have a predilection for the vermillion border of the lip 
which presents as cheilitis or as superficial ulcer or as crusting. While silvering or whitening of  
the vermillion border of the lip is a pathognomonic sign of DLE,51 early lesions appear as, 
superficial  painless  erythematous  patches  or  plaques  with  telangiectasia  and  may  exhibit 
atrophy,  erosion or  ulceration.  Chronic  lesions  typically  show sharply  marginated irregular 
atrophic  plaques  with  scalloped  radiating  white  striae  and  telangiectasia.  Nasal  mucosa  is 
involved in 9% of patients. Erythema in vulva is seen in 5%. In the eye they produce velvety 
edema  and  redness.  Erythematous  plaques  occur  on  lower  eyelid  in  6%  which  may  be 
associated with scaring of conjunctiva and symblepharon60,61.
Rarer presentations include vesicles, bullae,10 DLE in nail causing nail dystrophy and 
cutaneous  horns.61 Scarring  alopecia  is  the  end result  of  scalp  lesions.  Rare  complications 
include calcinosis10,62 and neoplastic changes10,49 like  basal cell epithelioma or squamous cell 
carcinoma. 
LE PROFUNDUS/LE PANNICULITIS/KAPOSI–IRGANG DISEASE: Kaposi in 1883 first 
described the subcutaneous nodules in LE. In 1940, Irgang introduced the term LE profundus.63 
Two  third  of  LEP  patients  had  DLE  lesions.  The  lesions  are  usually  non  tender,  firm, 
subcutaneous  nodules  which  are  sharply  defined,  one  to  several  centimeters  in  size.  The 
overlying skin may be normal but is frequently drawn inward  51 with saucerized depression. 
Ulceration may occur spontaneously  51  while, atrophy, scarring and cosmetic deformity may 
ensue as the nodules resolve. This condition occurs most often in the absence of associated 
internal  diseases.  LEP presented as  discrete  breast  nodules  -  lupus mastitis,  that  simulated 
breast carcinoma on mammogram. 51
HYPERTROPHIC LE /VERRUCOUS LE: 45 It  was  first  described by Behcet  in  1942,  as 
hypertrophic LE. Later, Vitto et al coined them as verrucous variant of DLE. Clinically the 
lesions often resembled keratoacanthoma, prurigo nodularis, Lichen planus or fibrokeratoma. 
The clinical course is marked by chronicity and absence of regression of lesions and resistance 
to therapy.
LE HYPERTROPHICUS ET PROFUNDUS: 10 Described by Behcet, starts as a violaceous, 
scaly, tender lesion. It rapidly enlarges and develops a warty hypertrophic surface with coarse 
adherent scales that form a hard brown black tar like plaque with rolled border and central  
crateriform  atrophy.  This  name  is  ambiguous  as  the  pathology  does  not  reveal  any  LEP 
features.
LE TUMIDUS: 39 Lesions are of violet red colour, the epidermis appears normal and there is 
little or no follicular plugging. The patches are well defined, raised and soft.
LE TELANGIECTOIDES:10  Described  by  Radcliffe  Crocker  in  1888,  is  characterised  by 
persistent blotchy reticulate telangiectasia and heals with punctate atrophic scarring. Scaling is 
absent.
CHILBLAIN  LUPUS: 44 Described  first  by  Jonathan  Hutchinson  in  1888,  which  is 
characterised by lesions of purplish blue discoloured patches or plaques on toes, fingers and 
face with little hyperkeratosis. The pulp of the fingers becomes atrophic but does not ulcerate. 
Patients usually have Ro antibody positivity and abnormal peripheral circulation and rarely 
cryofibriginogens or cryoagglutinins.
ROWELL’S  SYNDROME: 10 Described  by  Rowell  in  1963.This  is  unusual  variant  with 
transitions between SCLE and EMF. 30 The syndrome was described in DLE but it also occurs 
in SLE. It starts as a papule and later form rings with vesicles at the edge. Intense forms may 
show bulla, necrosis and ulceration. When the syndrome occurs in DLE, the lupus band test is 
positive in the discoid lesion and negative in EMF lesion. They characteristically have speckled 
ANA pattern and anti La positivity. 
LE/LP OVERLAP SYNDROME/RUBRIC LP: This refers to a condition in which the skin 
lesions present clinical, histologic and/or immunopathologic characteristics that may be typical 
for  both or either  of  the  disease  at  the same time.  46 It  is  usually  not possible  to assign a 
diagnosis of LE or LP alone. The lesions are characterised by large circumscribed atrophic 
patches  and  plaques  with  hypopigmentation  and  a  livid  red  to  violet  colour,  mild 
hyperpigmentation at the borders, minimal silvery scaling, fine telangiectasia and occasionally 
tending  towards  ulceration.37,46 Transient  bullae  and  verrucous  changes  may  occasionally 
develop.37 The lesions have a chronic course.
SUBACUTE CUTANEOUS LUPUS ERYTHEMATO  SUS:   (SCLE) 11,39,55 In  1977 Gilliam31 
introduced  the  term  SCLE  to  describe  a  distinct  type  of  cutaneous  LE,  which  had  been 
described in the past as superficial disseminated LE, subacute disseminated LE,11 pityriasiform 
LE,11, maculo papular photosensitive LE,11 and annular vesicular erythema.11 Approximately 
85% of all SCLE patients report of photosensitivity. It erupts as a small erythematous scaly 
papule  that  evolves  into  a  psoriasiform lesion  or  extends  peripherally  to  form annular  or 
polycyclic figurate configuration. The lesions tend to involve large confluent areas in contrast 
to the individual lesions that tend to remain separate and well circumscribed in DLE.  Follicular 
plugging is not a prominent feature. Greyish hypopigmentation is usually seen in the centre of 
the  annular  lesions  that  are  bordered  by  erythema and superficial  scales.  Vesiculo  bullous 
lesions  are  present  sometimes.  The  lesions  heal  without  scarring.  Residual  hypo  or 
depigmentation and telangiectasia may be present which resolve in months to years. Mucous 
membrane ulcers occur in 39% of patients particularly in patients with systemic manifestations. 
More  than  50%  have  non  scarring  alopecia.  Other  associated  cutaneous  findings  in 
uncomplicated cases include facial telangiectasia, livedo reticularis, periungual telangiectasia, 
vasculitis  and  cutaneous  sclerosis.  Most  patients  have  mild  systemic  complaints  and  50% 
satisfy ARA criteria54,55.
ACUTE  CUTANEOUS  LUPUS  ERYTHEMATOSUS  :  (ACLE)11,54,55 The  classic  malar 
butterfly rash or the more extensive morbilliform eruptions occurs at sometime in 30 to 40% of 
patients with SLE. ACLE is typically characterised by abrupt onset of confluent symmetrical 
erythema  and  edema  over  malar  eminences  and  last  few hours  or  days,  which  frequently 
coincides with the activity of disease. If it extends over bridge of nose it completed the body of  
classical butterfly rash but sparing nasolabial fold. Lesions do not leave a scar. Vesiculation, 
superficial  ulceration and crusting develop if  the  edema is  severe  and healing with hyper-
pigmentation is common. This acute edematous, erythematous eruption occurs most frequently 
after exposure to sunlight. The more widespread acute morbilliform or exanthematous eruption 
may resemble drug eruption which is also referred as “photosensitive rash” 
DRUG INDUCED LE:  2 7,28: Skin lesions are less common.29 Drugs like dapsone, sulphonamides 
and griseofulvin  can produce chronic  cutaneous  LE.  10  In  contrast  to  classical  SLE,  drug 
induced SLE is uncommon in blacks, has HLA-DR4 association, CNS and renal system is 
infrequently involved, low anti DNA antibodies, normal serum complement levels and more 
frequent  association  with  antihistone  antibodies.  ACLE,  Polyserositis,  hepatomegaly, 
polyarthritis, lymphadenopathy and pulmonary infiltration do rarely occur. 
BULLOUS LE:27,28 First description by Haradway in 1889.68 Bullous LE is apparently systemic 
in most cases. 69 It may be the sole manifestation of LE. Typically the lesions have little, if any, 
surrounding erythema, induration or inflammation. Usually erythema follows the rupture of the 
vesicle with ulceration and possible infection and scarring.  69 Bullous skin lesions that can be 
seen in LE patients can be specific or nonspecific. Specific bullous lesions can be seen with, 
TEN like SCLE and ACLE, vesiculobullous annular SCLE, bullous DLE. LE non specific 
bullous lesions included DA like cutaneous LE and Epidermolysis bullosa like cutaneous LE.
NEONATAL LE: LE in neonates may occur at birth, within few hours or upto 6 weeks.  52,71’72 
This disorder is by transplacental passage of maternal antibodies. Cutaneous manifestations are 
seen in 50% of cases. Most common finding is erythematous, scaly eruption confined mostly to 
head and neck. Lesions over orbital skin called as Racoon sign or Owl eye. Rashes improve 
within few months with residual dyspigmentation.72 Systemic involvement like congenital heart 
block, hematological and hepatic manifestations are common. Neonates are Ro/SSA antibody 
positive in which 52 KDa protein and 60 KDa protein of Ro antibody are responsible for CHD 
and cutaneous lesions respectively27.
CHILDHOOD LE:72,73 DLE is rare in children. The common age of occurrence is between 8 
and 10 years of age. Lesions are the same as adults52 but they encounter severe disease and 
often associated with hepatosplenomegaly and lymphadenopathy. Other types of CLE are also 
rare. 
SLE IN PREGNANCY:27,28 Fertility is not affected but there are more chances of recurrent 
abortion  and  poor  fetal  outcome  particularly  when  associated  with  APLS.  Renal  function 
detoriates if it has already affected.
SLE IN ELDERLY:27,28 It is associated with HLA DR3, increased incidence of lung disease and 
anti Ro and La antibody.
ANTIPHOSPHOLIPID ANTIBODY SYNDROME: This is a procoagulant syndrome. This in 
SLE  is  associated  with  recurrent  abortions,  thrombosis,  ulcer,  livido  reticularis,  purpura, 
ecchymosis, retinal changes. This occurs due to interruption in protective function of beta2 
microglobulin against coagulation.
URTICARIAL VASUCLITIC LE: 39  This is probably an LE subset with  sense of combination 
of SCLE with leukocytoclastic vasculitis. Clinically there are patches of erythema as well as 
persistent urticaria with some hyperpigmentation and purpura.
COMPLEMENT  DEFICIENCY  LE: 36 Deficiency  of  early  components  of  complement 
especially C2 is well known. 60% of the persons with C2 deficiency may be affected with SLE 
or  DLE.  Striking  feature  is  the  presence  of  LE  like  rash  involving  sun  exposed  areas. 
Laboratory abnormalities and systemic associations are minimal.
ANA NEGATIVE  SLE: 39 Malar  rash  and  annular  type  of  lesions  may  be  prominent. 
Photosensitivity and oral ulcerations are common and the systemic involvement is usually less 
and hence prognosis is good.
URTICARIAL PLAQUE:51 The  commonest  manifestation.  It  is  a  reddish  purple  plaque, 
relatively fixed in shape and time, showing no atrophy or scaling, and occurs usually on the 
face.  It  occurs  in  both  cutaneous  and  systemic  LE.  In  the  systemic  form  a  more  acute 
violaceous,  urticarial,  papular lesion that  look like hives except for  their  violaceous colour 
occurs that lasts only for few days and disappears without scarring. Urticaria in SLE is usually 
the cutaneous expression of the underlying circulating immune complex. Chronic urticaria may 
be a presenting manifestation of LE but is very uncommon.
ALOPECIA (40 to  60%):11,54 Scarring  alopecia  is  a  sequlae  of  DLE.  Diffuse  non scarring 
alopecia occurs during the acute toxic exacerbation of systemic disease. A receding frontal hair 
line with broken hairs has been called "lupus hair” which is seen in 6% of patients..  11,54 Other 
causes of non scarring alopecia may include drugs, stress and telogen effluvium.
PHOTOSENSITIVITY REACTIONS:51 Photosensitivity  reactions  include  atrophic  scaling 
plaques, fixed urticarial plaques, transient urticarial papules and a persistent violaceous flush 
over  the  face  and  ‘V’ of  the  neck.  The  lesions  may  persist  for  hours,  days  or  weeks. 
Photosensitivity  reactions  may  cause  fatal  exacerbation  of  the  disease.  Although,  most 
photosensitive patients react to the sunburn portion of the UV spectrum, but rarely to blue 
green radiation emitted by fluorescent lamps54.
VASCULAR  LESIONS  (50-70%):11,54 Three  types  are  commonly  seen  namely  linear 
telangiectasia  involving the posterior nail fold and cuticle, erythematous polyangular macules 
and lastly papular telangiectasia (45-65%). Discrete papular telangiectasia on the palms and 
finger is characteristic sign of SLE.51 Discrete erythema with or without scaling is sometimes 
observed  over  the  interphalangeal  and  large  joints  and  the  periorbital  tissues.51Centrifugal 
annular erythema is rarely seen.10
RAYNAUD’S PHENOMENON: 51 (30%) May precede or follow LE lesions. Digital gangrene 
and ulceration may be produced by severe Raynaud's phenomenon. 
DERMAL AND SUBCUTANEOUS VASCULITIS: Dermal vasculitis may produce palpable 
purpura occurring in the lower extremities, small dermal ischaemic infarcts with ulcerations, 
peripheral gangrene, painful subcutaneous nodules, chronic and recurrent ulcers, especially in 
the legs and forearms (2-8%) and livedo reticularis (10%).11Purpura can also occur secondary 
to thrombocytopenia and steroid therapy. 10
ATROPHIE BLANCHE:  The lesions closely resembling malignant atrophic papulosis.10 Small 
splinter haemorrhages are rarely seen. 13
SUBCUTANEOOS  NODULES (Rheumatoid  nodules  5-10%):11,54 Usually  non  tender  and 
cartilagenous in consistency and may occur over the proximal inter phalangeal joints, elbow, 
dorsum of the wrists, extensor surface of the extremities and occiput.
RECURRENT SUPERFICIAL AND DEEP THROMBOPHELBITIS:  (5%-10%)  May be an 
early sign of SLE. 51
GENERALISED HYPERPIGMENTATION:  This may be  seen11,54  in 10%.
BULLOUS LESIONS:(< 5%) Including haemorrhagic bullae can occur in LE.11,54
MUCOUS MEMBRANE LESIONS: They are often histologically LE specific usually occur 
during  acute  flares  of  the  disease  and  painless.10,11,51   Palate  is  most  commonly  involved 
followed by cracked edematous crusted lips. Mucosal haemorrhage, painful erosions, shallow 
ulceration  surrounded  by  erythema,  gingivitis  and  palatal  erythema  may  also  occur  as 
nonspecific lesions. Nasal septal, vulva and perianal ulcers may rarely occur, especially during 
disease activity.     
SCLERODACTYLY:(10%11)  Sclerodactyly and clubbing is rarely seen.10 
OTHERS:  Erythema multiforme may also be an expression of increased disease activity in 
SLE.51 Calcinosis can develop in subcutaneous tissue, muscle and periarticular structures in 
longstanding disease.11  Other rare manifestations include poikiloderma atrophicans vasculare, 
erythromelalgia,  pyoderma  gangrenosum  and  panniculitis.  Allergic  reactions  like  allergic 
dermatitis, rhinitis, asthma or food or drug allergies have a higher than normal incidence in 
SLE. 13
OVERLAP  SYNDROMES:  Variable  signs  of  more  than  one  disease  are  shared  in  this 
condition for example, Dermatomyositis and LE. 27 In some cases such a differentiation is not 
seen  and  in  such  cases,  a  diagnosis  of  undifferentiated  connective  tissue  disease  seems 
warranted. 74
MIXED CONNECTIVE TISSUE DISEASE: Was first described by Sharpe et al in 1971.74 The 
most common presentations include Raynaud’s phenomenon, joint pain and cutaneous LE.  75 
Among the cutaneous LE, the majority have chronic discoid LE, minority have SCLE, and 
rarely have ACLE, LEP and others.75 Sharpe et al found lupus like rash, SCLE and DLE in upto 
50% of cases. The defining feature of this disease is high titre of haemagglutinating antibody to 
the ribonuclease sensitive component of extractable nuclear antigen (ENA). 51,76
SJOGREN  SYNDROME:   This  syndrome  also  can  have  LE  lesions  and  immunological 
findings of LE syndrome. 30
SENEAR USHER SYNDROME:  77   The exact categorization as a distinct subset of  Pemphigus 
erythematosus or LE or co-existence of Pemphigus erythematosus and LE is still under debate 
though Chorzelski et al78 had concluded that in the majority of cases reported, there is co-
existence of pemphigus erythematosus and LE, both clinically and immunologically.
SYSTEMIC  MANIFESTATIONS  IN  LUPUS  ERYTHEMATOSUS:  Various  studies  show 
different  percentage  incidence  of  various  organ  involvement.10,11,13,21,33,47,79 Constitutional 
symptoms include fever, myalgia, malaise, weakness, anorexia, weight loss etc.
MUSCULOSKELETAL SYSTEM:13,79 This is the commonest system to be involved. Arthritis 
without erosion or deformity, migratory polyarthritis, joint effusions, persistent arthralgia with 
stiffness, and aseptic necrosis of the bone occur. One of the hall mark of lupus joint symptom is 
more symptom and less deformity. Myopathy and lupus foot are rare occurrence.
CARDIOVASCULAR  SYSTEM:(50%)79 Pericarditis,  pericardial  effusion,  myocarditis, 
conduction defects, cardiac failure, heart murmurs, Libmann Sack endocarditis,  hypertension, 
cardiomegaly etc.
RESPIRATORY  SYSTEM:(45%)79 Pleurisy,  pleural  effusion,  pneumonia,  pulmonary 
vasculitis, etc.
RENAL SYSTEM:(53%)79  Hematuria, localised, diffuse and membranous glomerulonephritis, 
nephrotic syndrome etc.
CENTRAL  NERVOUS  SYSTEM:(26%)79 Peripheral  neuritis,  convulsions,  psychosis, 
hemiparesis,  aphasia,  cranial  nerve  palsies,  subarachnoid  haemorrhage,  Guillain  Barre 
syndrome, chorea and others.
GASTROINTESTINAL  SYSTEM:(53%)79 Nausea,  vomiting,  diarrhoea,  ulcerative  colitis, 
dysphagia, abdominal pain, hepatomegaly(25%), splenomegaly(10%), jaundice etc.
LYMPHATIC SYSTEM: Generalised lymphadenopathy (59%).79
EYE  INVOLVEMENT: 13 Cytoid  bodies,  exudation,  haemorrhage,  arteriolar  narrowing, 
conjunctivitis, episcleritis, papilloedema, optic atrophy etc.
BONE CHANGES: These include avascular necrosis, cysts and sclerosis.
INTER RELATIONSHIP AND IMPLICATION OF CUTANEOUS LE IN SLE  76  :    
Cutaneous LE can be acute, subacute or chronic and scarring or non scarring. DLE is on 
the benign end of the LE spectrum and SLE is on the other pole. All variations occur between 
the cutaneous and systemic form of the disease and the host immune response is critical in 
disease expression. There is a 'Grey area' between DLE and SLE as defined by ARA criteria.54 
In this area are those patients who have DLE with mild serological or clinical symptoms of  
systemic disease. The chronic cutaneous lesion in DLE and SLE are identical clinically and 
histologically. 51,80 DLE is  the  presenting  manifestation  in  approximately  2  to  10% of  the 
patients with SLE and. approximately 15-20% of the patients with SLE4,10,13,42 eventually have 
DLE lesions.10,13,54,55 Females developing DLE before the age of 40 years and those with HLA 
B8 are more  prone to develop SLE. 17 Patients with DDLE and DLE lesions below the neck, 
have more frequent clinical and laboratory abnormality suggestive of SLE.  50,81,82 Patients with 
DLE develop SLE particularly after exposure to sun light, X-ray, chronic infection or drugs. 30 
to  50%  of  DLE  patients  intermittently  exhibit  abnormal  lab  findings  such  as  leucopenia, 
increased ESR, mild anemia etc. Nearly all patients with DLE and extra cutaneous disease have 
positive ANA test.34
SLE  patients  with  DLE  lesions  usually  have  a  better  overall  prognosis  than  those 
patients who do not have DLE and these patients rarely develop renal insufficiency.  47,54,70,82,83 It 
is impossible to predict whether a DLE patient will eventually go in for SLE or not from the 
morphological or clinical picture of DLE alone. 51
About 50% of the patients with LEP go in for SLE56. 84SCLE manifests in approximately 
10% of the SLE patients and 50% of patients with SCLE satisfy the ARA criteria for SLE. 
55ACLE is the commonest of the specific cutaneous LE to be the presenting manifestation of 
SLE10 and 30 to 40% of SLE patients have ACLE at sometime of the disease.55 It reflects the 
activity of the systemic disease. The presence of overlapping cutaneous features of DLE and 
SCLE may point towards the presence of probable development of SLE. 85The prognosis in 
SLE worsens when the spectrum moves from the DLE to ACLE. 
DIFFERENTIAL  DIAGNOSIS:   10,11,13,51
DLE needs to be differentiated from polymorphic light eruption, seborrheic dermatitis, 
psoriasis, acne rosaceae, tinea faciei, granuloma teenei, leishmania recidivans, sarcoidosis and 
others. Scarring alopecia due to DLE should be differentiated from lichen plano pilaris and 
pseudopelade  of  Brocq.  SCLE  should  be  differentiated  from  psoriasis  and  psoriasiform 
syphilide. ACLE should be differentiated from erysipelas, leprosy in reaction, Senear-Usher 
syndrome, Sweet’s syndrome, drug eruption and others. Bullous LE should be differentiated 
from eruption  and  others.  Bullous  LE should  be  differentiated  from erythema  multiforme, 
pemphigus, pemphigoid and other bullous dermatosis. LEP should be differentiated from other 
causes of panniculitis especially connective tissue pannicultis and Weber-Christian disease.
HISTOPATHOLOGY:
The histopathologic features of LE are well known and are usually considered to be 
diagnostic. 10-13  But  different  clinical  types  cannot  be  reliably  distinguished  on  histological 
grounds alone.12 It is opined that most of the Pathologists had not tried to separate the different 
LE subsets,  the  primary  reason being,  they considered the  variations  in  the  findings  to  be 
related to the age of the lesion, the more aged showing more changes. 
DLE  lesions  show  hyperkeratosis,  keratotic  plugging  (both  follicular  and 
extrafollicular), epidermal atrophy, liquefaction degeneration of basal cells, squamatization of 
basal cell layer,88 thickening of the basement membrane zone (BMZ), edema of the papillary 
dermis,  and  lymphohistiocytic,  mononuclear  and  macrophage   infiltrate.  Liquefaction 
degeneration  of  the  basal  cell  has  been  considered  as  the  most  important  finding  in  the 
diagnosis of cutaneous LE12,88 The lymphohistiocytic infiltrate is patchy and distributed around 
the blood vessels,  appendages and also independently in the papillary and reticular dermis, 
rarely extending upto the subcutaneous fat. The infiltrate may extend into the appendageal epi-
thelium with vacuolation and liquefaction degeneration of the basal cells, which in the absence 
of epidermal basal cell degeneration may be diagnostic.88 88 Civatte bodies (Dyskeratotic cells) 
and incontinence of melanin into the upper dermis and increased production of melanin are 
usually seen. 88 Dermal edema, fibrinoid deposits and focal dermal hemorrhage may be present. 
Increased deposits of acid mucopolysaccharide also been observed in special stains. Excepting 
for fibrinoid deposit, these changes are characteristically seen in DLE. Atypical keratinocytes 
may be seen occasionally in chronic lesions of DLE. 
In ACLE, the lesions show sparse dermal infiltrate, focal liquefaction degeneration of 
basal cells and upper dermal edema. Epidermal necrosis may be noted in severe forms12. In 
SCLE,  the  hydropic  degeneration  of  the  basal  cells  and  edema  of  the  dermis  are  more 
pronounced  than  DLE  lesions,12 but  the  hyperkeratosis  is  less  and  inflammatory  infiltrate 
independent and around the appendages is confined to the upper third of the dermis only.87 The 
oedema may be severe enough to produce clefts and even vesicles between the epidermis and 
dermis.12 Focal extravasation of erythrocytes and fibrinoid deposits may be seen.  The presence 
of hyperkeratosis, BMZ thickening, extensive follicular damage, dense leukocytoclastic infil-
trate  and involvement  of  the  deep dermis  favoured  the  diagnosis  of  DLE.  While  minimal 
changes of this type and sparing of the follicles and deep dermis favoured the diagnosis of 
SCLE.  Liquefaction  degeneration  was  considered  as  one  of  the  unimportant  factor  in  the 
diagnosis of SCLE. They concluded that irrespective of the age of the lesion, the two subtypes 
can  be  distinguished  in  that  the  lesions  of  SCLE  were  superficial  with  slight  follicular 
involvement, while those of DLE were more extensive and deeper.
LEP shows septal and lobular panniculitis composed of lymphoid cells, plasma cells and 
histiocytes56  occasionally  forming  germinal  centers,  necrobiotic  changes  with  fibrinoid 
deposits,  vascular changes like thrombosis,  perivascular fibrosis and calcification are rarely 
seen.12 The overlying epidermis and dermis may show DLE changes or changes of verrucous 
type i.e. hyperkeratosis,  hyperplasia and papillomatosis. 56
             In LE/LP overlap syndrome, some may show findings suggestive of LP, some LE and 
in some both. It appears that on histological grounds clear differentiation may be impossible 
and only the subsequent evolution may make a diagnosis possible.90
In  bullous  LE,  bulla  is  subepidermal.69 Mucosal  LE  shows  parakeratosis  or 
hyperkeratosis,  liquefaction  degeneration  of  basal  cell  layer,  degeneration  of  collagen  and 
dense inflammatory cells in the submucosa, sometimes in a perivascular pattern. 
ELECTRON MICROSCOPIC EXAMINATION:12 
                EMS of the specific cutaneous lesions of LE show marked vacuolation in the  
cytoplasm of the basal cells, numerous greatly elongated narrow cytoplasmic projections in to 
the dermis with surrounding basement membrane. The basal cells progress to disintegration 
with necrosis of the cytoplasm, giving the impression that the basal cells are the primary site of  
change in cutaneous LE. The colloid bodies appears as homogenous eosinophilic ovoid bodies, 
of 20 nm in diameter filled with filaments of 6 to 8 nm in diameter. They are largely located in  
the  papillary  dermis  but  sometimes  are  seen  in  the  lower  epidermis.  They  contain  fibrin,  
immunoglobulin and complement.90 
CUTANEOUS IMMUNO FLOURESCENCE TEST (LUPUS BAND TEST-LBT):
In 1963, Burbham et al first reported the presence of immunoglobulin (Ig) at the dermo-
epidermal junction (DEJ) in patients with LE. 7 Cormane (1964) pointed out Ig and complement 
(C) deposition at DEJ in clinically normal skin of patients with SLE.91 The test entails the 
Direct Immunoflourescence (DIF) testing of involved and uninvolved sun exposed skin for the 
purpose of diagnosis, and of uninvolved sun protected skin for the purpose of prognosis. For 
this  purpose  skin biopsy  specimen is  transported in  Micheli’s  medium and incubated  with 
fluorescent tagged IgG/IgM and viewed under fluorescent microscope26.                        
All  three  major  immunoglobulin  classes  (Ig G,  M,  A) and a  variety  of  complement 
components  may  be  present  in  the  subepidermal  deposits.  The  pattern  is  usually  granular, 
thready, stippled and continuous, but may be homogenous in a small percentage. Stippled band 
occurs in uninvolved skin, thready band in new lesions and homogenous band in older lesion. 
IgM and IgG are most frequently detected in the subepidermal deposit while properdin along 
with fibrin is also deposited occasionally.26,27
When involved skin were tested, Ig and complement deposition are seen between 50% 
to 90% of the specimens in DLE, between 50%  to 94% in SLE and around 60% in SCLE.  92 
When uninvolved sun exposed skin  were  tested,  it  was  almost  negative  in  DLE,  and was 
positive in 81% to 90% with SLE and 26% with SCLE.  92 When uninvolved sun protected skin 
was tested, 50% to 83% of specimens were positive in SLE, 46% in SCLE and was negative in 
DLE.92  The  basement  membrane  phenomenon  can  be  demonstrated  in  uninvolved  skin  in 
patients  with  transitory  type  of  DLE.  The  percentage  of  positive  LBT in  uninvolved,  sun 
protected skin is correlated with the severity of renal involvement. In addition, the deposits in 
normal skin may be found in SLE patients who lack skin involvement altogether. 93
HISTOLOGICAL DIFFERENTIAL DIAGNOSIS:12 
Lichen planus, polymorphous light eruption of the plaque type, lymphocytic lymphoma, 
lymphocytoma  cutis  and  lymphocytic  infiltration  of  Jessner.  Bullous  LE  should  be 
differentiated  from  EMF,  dermatitis  herpetiformis,  bullous  pemphigoid  and  other  bullous 
dermatoses with subepidermal bulla.
LABORATORY ABNORMALITIES OF LE:
The  lab  abnormalities  increase  as  the  spectrum  moves  from  DLE  to  SLE.  Before 
investigations are planned they can be categorized as biochemical abnormalities, ANA pattern 
and its titre, investigations pertaining to systemic involvement.
BIOCHEMICAL ABNORMALITIES  : 
Since ACLE is usually the scene of SLE the lab abnormalities parallel those of SLE. 
Literature report shows leukopenia in 37%, thrombocytopenia in 21%, anaemia in 75%, raised 
serum gamma globulin in 29%, LE cell was positive in 83%, VDRL shows false positivity in 
25%, while rheumatoid factor and positive coomb’s test was seen in 37% and 15% respectively. 
Cryoglobulins are most often present in patients with lupus nephritis, raynaud’s phenomenon, 
gangrene  while  APL  antibodies  are  seen  in  patients  with  repeated  abortion,  gangrene, 
thrombosis  anywhere,  livedo reticularis.  Complement  levels  are  low in patients  with lupus 
nephritis 26,27,94,95. 
In patients with SCLE leucopenia was seen in 19%, anaemia in 15% increased ESR in 
59%, LE cell test positivity in 56%, increased gamma globulin in 30%, false positive VDRL in 
30%, Rheumatoid factor positivity in 17%, ANA in 30% and Anti DNA in 57%94,95
 Studies of abnormal lab values in DLE has shown leucopenia in 12.5%, anaemia in 
30%,  thrombocytopenia  in  5%,  increased  ESR in  26%,  increased  serum globulin  in  29%, 
positive RF in 15%, false positive VDRL in 5%, positive LE cell phenomenon in 1.7%, positive 
ANA in 35%, positive cryoglobulin in 2.5%. The diversity of results in all these spectrum is 
due to the spectrum of disease per se in its pathogenesis26,94 It has been established however, 
that patients in whom the disease changes from DLE to SLE have persistent multiple abnormal 
lab findings from the beginning. This is in contrast to cases of simple DLE in which most  
abnormal lab findings, if present at all are transient more over, no single lab abnormality value 
in a patient with DLE can tell whether there will be an conversion to SLE or not. 
ANA PATTERN:
         ANA are family of auto antibodies directed against contents of cell nucleus like dsDNA, 
ENP (extractable nuclear proteins), Histone, nuclear RNA. ANA titre measures the pattern and 
amount of auto antibodies. Substrates used are rat liver, mouse liver and human laryngeal cells  
(Hep-2 cells). The pattern depends on the type of antibodies and substrate used. Hep-2 cells are 
widely used now a days for its high specificity and sensitivity.26,27  Patient’s serum is incubated 
with  Hep-2  cells  along  with  the  fluorescence  tagged  auto  antibody  and  viewed  under 
fluorescence microscope. Then the pattern is compared with standardized charts. Various other 
quantitative methods as mentioned above are also used, which measures antibody in titres90,92. 
Various  types  of  ANA pattern  (table  6)  using  Hep-2  cells  are  seen  which  includes 
homogenous, fine speckled, discrete speckled, nucleolar pattern. Nucleolar pattern is further 
divided into homogenous speckled and clumpy shows pattern of ANA, associated antibodies, 
their target antigen and their significance.26,93,95 Homogenous ANA pattern is equivalent to LE 
factor and it’s the most common pattern seen in SLE. Peripheral rim pattern is most commonly 
associated with active disease, while peripheral shrunken pattern is most commonly seen in 
patients with lupus nephritis.26,92,93  Peripheral shrunken pattern is seen 1-2 wks before disease 
exacerbation and it is an indicator of poor prognosis. Presence of anti Sm antibody indicates 
lupus nephritis. LE cell test which was used a decade ago is obsolete now.
Table 6
PATTERN TARGET SITE
ASSOCIATED 
ANTIBODIES
ASSOCIATED 
DISEASES
CLINICAL 
SIGNIFICANCE
Homogenous Chromatin
Antihistone Drug induced SLE
less alopecia, less 
anemia ,less CNS 
&Renal problems
Anti DNA SLE
Rim 
Peripheral
Chromatin 
Nuclear 
membrane
Anti DNA, Anti 
laminin SLE
Peripheral Shrunken 
– Poor Prognosis lupus 
nephritis
Line Speckled Nuclear RNP
Anti Sm SLE
More Specific, 
associated with Renal, 
CNS  Vasculitis
Anti La/SSB Rowells Syndrome
Anti Ro/SSB
Photosenitivity, serositis, 
CLE, Chilblain lupus, 
Neonatal LE with heart 
block
Anti KU SCL-70 Scleroderma
Discrete 
Speckled Chromatin Anticentromear CREST
Nucleolar
Nucleolar RNP Anti U3RNP Scleroderma
Nucleolar Anti RNA Polymerase
Components Anti Pm SCI
 
 INVESTIGATIONS PERTAINING TO SYSTEMIC INVOLVEMENT:  
As  SLE  involves  almost  all  viscera,  investigations  are  done  depending  upon  the 
symptoms. All  base line investigations like LFT, RFT, urine routine, USG abdomen, CXR, 
ECG is done. Expanded modes of investigations are done on individual needs which are shown 
in table 7.
Table 7
S.NO PATHOLOGY INVESTIGATION
1 CNS symptoms CT, MRI
2 Gangrene, ulcer APL levels
3 Livedo reticularis Cryoglobulins
4 Repeated abortions Cold agglutinins, APL
5 Cardiac ECHO
6 Respiratory CXR, HRCT
7 Lupus nephritis Renal biopsy, 24 hrs urine protein,C3, C4 
levels
6 Lupus retinopathy Retinoscopy, angiography
7 GIT Endoscopy
8 Avascular bone necrosis MRI, lupus anticoagulant
 
All the above investigations are considered and treatment and follow up are made based 
on them since SLE is a multi systemic disease. 
TREATMENT  : 
LE  may  subside  spontaneously  or  remain  as  a  minimal  problem  or  progress  with 
resultant  scarring,  so therapy should be as conservative  as possible  and should be a  multi  
disciplinary approach.  Treatment can be divided into general care,  treatment of the disease 
proper.
General  care  includes  education  to  the  patients  and  family  regarding  the  nature  of 
progression of the disease, avoidance of phototoxic drugs, pregnancy complications. Avoidance 
of sun exposure is one of the mainstays of treatment, which includes photoprotective clothings, 
and using  sunscreens  of  SPF>3028.  Counseling regarding good hygiene,  early  treatment  of 
infections, avoidance of precipitating factors like stress, alcohol should be stressed. 
Both topical and systemic drugs are used depending upon the need. Class I steroids like 
clobetasone  propionate  0.05  %  can  be  given  as  BD  dose  for  2  wks  (or)  Betamethasone 
dipropionate 0.05% twice weekly for 2 wks followed by 2 wks rest can be given for severe 
leison to minimize the side effects.27 Intralesional  triamcinalone acetonide 2.5-5mg / ml can be 
given upto 3 ml in patients with DLE which is more resistant and hyperkeratotic26,27,96.
             Since the first use of quinacrine hydrochloride in 1940, antimalarials has been used as 
the mainstay of treatment for the disseminated type of cutaneous LE, DLE, SLE, LEP and other 
types and for cases resistant to topical steroids28. Chloroquine sulphate in the dose of 4mg /kg 
(or) 200 mg BD initially for 2-3 wks followed by 200 mg OD can be prescribed27. Progress is 
assessed after 6 wks and if there is improvement, the drug is continued for not more than 6 
months, due to the serious toxic effects like retinal damage97,26. A dose related side effect may 
ensure. Hydroxy chloroquin may be preferred for its less ocular toxicity. This drug is used in  
6.5 mg/kg dose for 6-8 wks then tapered and may be continued for 1 year27,95,96.  Quinacrine can 
also  be  used  in  a  dose  of  100  mg/day  for  4-6  wks.  75%  of  the  patients  are  helped  by  
antimalarials  but  50%  show  relapse  in  6  months  of  stopping  the  treatment.   A careful 
ophthalmic examination should be performed prior to treatment and 3-4 months interval, while 
on antimalarials97.
              Immunosuprressants and cytotoxic drugs are used in patients with extensive, skin  
diseases which are severely symptomatic and in whom there is severe systemic involvement.  
Steroids in the form of pulse methyl prednisolone (or) Prednisolone 1-2 mg/kg can be given97,98. 
Later once the desired response is attained steroid is stopped by tapering. Various other steroid  
sparing drug and combination drugs can be used in patient to reduce the side effects of steroids 
and in patient who are not responsive to steroids alone.
Azathioprine a steroid sparing drug in a dose of 1.5 – 2 mg /kg/ day, mycophenolate 
mofetil  a  purine  analogue  in  a  dose  of  2.5  – 3mg/day,  methotrexate  15-20  mg/wk, 
cyclophosphamide  500-700mg/m2,  cyclosporine  2-5  mg/kg  are  various  other 
immunosuppressants  are  used  in  severe  cases.  97,98,27  Leflunomide  which  is  an  inhibitor  of 
denovo pyrimidine synthesis  used in rheumatoid arthritis can also be used here.
Various other non immune suppressive like dapsone can be started in a dose of 50mg/d 
and can be raised up to 100mg/d98,99. Retinoids in the form of   isotretinoin and acetretin in the 
dose of 0.5-2mg /kg/day and 10-50mg/d respectively is used. 
Thalidomide  a  TNF  alfa  inhibitor  is  tried  in  refractory  cases  in  the  dose  of  100-
300mg/d98.  Lenolidomide,  a  thalidomide  analogue  is  more  efficacious  but  with  equal  side 
effects. Other drugs like gold, clofazamine, Vitamin E, Pheytoin, sulfasalazine are also in use. 
Recently  advanced  biologicals  like  Anti  TNF  alfa  medication  (i.e)  Itarnacept, 
Adalimumab, Infliximab can be tried in recalcitrant LE but these agents are also well known to 
induce both SLE and CLE. Biologicals like Rituximab, a genetically engineered monoclonal 
antibody  of  CD20,  Eprutuzumab,  a  monoclonal  antibody  against  CD22  B  Cell  antigen, 
Bisulimumab, a monoclonal antibody to B lymphocyte stimulation, Abatacept ,a fusion protein 
which modulates T cell activation by blocking costimulator signals, Efalizumab monoclonal 
IgG antibody directed against CDla/LFA can also be tried for resistant cases. IVIg in the dose 
of 2g/kg/day over 2-5 days acts by neutralizing antibody26,27,98. Stem cell transplant and anti B 
cell antibodies are now tried experimentally.27,28,98
Physical  methods like  freezing with liquid nitrogen,  CO2 snow sometimes results  in 
clearing,  painting with TCA has also been used with some success.  Treatment of  systemic 
disease largely depends on the system involved and the extent of involvement. The main stay of 
treatment of systemic diseases includes immunosuppressants and biologicals 26,27.
AIM OF THE STUDY
1. To study the incidence of SLE in Government General Hospital,  Chennai during the 
period between August 2007 to September 2009.
2. To study the incidence of various cutaneous spectrum of SLE.
3. To study the age and sex incidence.
4. To study the commonest site of lesions in various spectrum.
5. To study the precipitating and exacerbating factors. 
6. To study the various mucocutaneous presentations.
7. To study relevant laboratory abnormalities.
8. To study the associated disorders.
9. To study the histopathological features and Immunofluorescence pattern.
MATERIALS AND METHODS
45 cases of systemic lupus erythematosus were collected from the patients attending the 
Skin  &  Rheumatology  department,  Govt.  General  Hospital,  MMC  from  August  2007  to 
September 2009.
Patients  who either  fulfilled ARA criteria  (or)  ANA positivity  were  included in  our 
study. A detailed history regarding the onset, progress, precipitating (or) exacerbating factors, 
recurrence, number, size, morphology, distribution and sequelae of the lesions was obtained. 
Symptoms related to cutaneous lesions and internal systems were noted in all  cases.  In all  
female patients detailed menstrual and obstetric history was taken to look for anti phospholipid 
syndrome. Detailed laboratory investigations including biopsy were done.
          Then depending on the  above  information  conclusions  and discussions  were 
formulated.  All these patients were followed up for 2 years and the patients were categorized 
according to their clinical features into the following groups.
1. Chronic Cutaneous Lupus Erythematosus (CCLE):  It  include (a)  Discoid LE (DLE) 
Characterised  by  well  defined  erythematous  plaques  with  thick  adherent  scales  and 
keratotic  plugging,  peripheral  hyperpigmentation  and  central  hyper,  hypo  (or) 
depigmentation, atrophy, telangiectasia, and scarring. It was subdivided into localised 
type,  when lesions were restricted to head and neck and disseminated type (DDLE) 
when lesions were present elsewhere also, and (b) Lupus erythematosus panniculitis, 
characterised by well defined, firm, non tender, subcutaneous plaques with normal (or) 
indrawn  overlying  skin  and  with  (or)  without  ulceration.  Presence  of  DLE  lesion 
elsewhere was taken as confirmatory evidence for the diagnosis.
2. Subacute  Cutaneous  Lupus  Erythematosus  (SCLE)  Characterized  by  annular  (or) 
polycyclic erythematous plaques with superficial scales (or) psoriasiform lesions, having 
a tendency to coalesce to form large confluent  areas with hypo pigmentation in  the 
centre and erythematous scaly margins without scarring.
3.  Acute Cutaneous Lupus Erythematosus (ACLE) characterised by acute erythema with 
oedema and confined mostly to the malar area (or) other sun exposed areas. It lasts for 
few  days  to  weeks  and  heals  with  hyperpigmentation.  The  lesions  are  sometimes 
generalised with morbilliform (or) exanthematous eruptions and are characteristically 
associated with other cutaneous lesions and systemic manifestations. 
The  morphological  description  given above  was  taken as  “Classical  form”  for  each 
specific group.
Biopsy of the skin lesions was done in all patients to confirm the clinical diagnosis of 
Lupus Erythematosus (LE). The characteristic and diagnostic histopathological findings in LE 
are, 1) Hydropic degeneration of the basal cells  of  the  epidermis  (or)  the  follicles, 2) Patchy 
lymphohistiocytic  infiltrate  both   independently   and   around   the   blood   vessels   and 
appendages.
3) Degenerative changes in connective tissues like hyalinization, oedema, mucin and fibrinoid 
change.
In addition to the above findings the presence of following histopathological features 
were taken as suggestive evidence for specific clinical type. 
DLE – Hyperkeratosis, keratotic plugging both follicular and extrafollicular, epidermal 
atrophy, depth of inflammatory infiltrate extending upto the deeper dermis and mucin deposits. 
SCLE –  Absence  (or)  minimal  keratotic  plugging,  no  epidermal  atrophy,  vesicular 
changes in active borders, focal hydropic degeneration of basal cells and sparse inflammatory 
infiltrate confined to the upper third of the dermis, dermal edema, extravasation of  RBC’s and 
dermal fibrinoid deposits
ACLE – Increased degree of hydropic degeneration of basal cells, sparse dermal cellular 
infiltrate and upper dermal oedema and rarely epidermal necrosis.            
All  case  selected  were  examined clinically  to  rule  out  any  systemic  manifestations. 
Depending upon the systemic symptoms patients were investigated in detail pertaining to the 
system suspected to be involved.
CBC, platelet count, urine for albumin, sugar and deposits, RFT, LFT, CRP, VDRL, RF,  
CXR, and ECG were done to all patients. APL antibodies were done in all suspected patients. 
Delivered new born of SLE mother were screened for heart block. Patients with symptoms 
suggestive of  renal  problems and vasculitis  were investigated for  C3 and C4 levels.  Renal 
biopsy was also done for few patients as suggested by nephrologist. Doppler was done for 
lower limb vessels for patients with gangrene and legulcer. Direct Immunofluorescence and 
Indirect  Immunofluorescence  (IDIF)  were  done  in  few  patients.  With  all  the  above 
methodologies and investigation, results were formulated and conclusions were drawn.
OBSERVATION & RESULTS
I.  INCIDENCE OF SLE:
Total number of patients attended skin op between August 
2007 to September 2009 52,369
Total number of patients with SLE 45
Incidence 0.08%
II. DISTRIBUTION OF THE CASES IN THE DISEASE SPECTRUM:
Total no. of 
cases
CCLE
SCLE ACLE
DLE LEP
45
16
(39.92%)
1
(2.86%)
3
(8.48%)
25
(47.94%)
In our study out of total 45 cases, majority of them were ACLE, followed by CCLE and 
SCLE.
III.  AGE INCIDENCE:
Age
CCLE
SCLE ACLE Total Percentage
DLE LEP
11-20 4 - - 4 8 17.77%
  21-30
   8 -       2       10 20 44.44%
31-40
3 1 1 9 14 31.11%
41-50
1 - - 2 3 6.66%
75.55% of the patients were between the age group 20 to 40 years. Out of them, 42.22% 
were ACLE patients, 26.66% were CCLE patients and 6.33% were SCLE patients.
IV.SEX INCIDENCE:
CCLE SCLE ACLE TOTAL
Sex M F M F M F M F
Number of 
cases
2 15 0 3 4 21 6
(12%)
39
(88%)
In our study male: female ratio is 1:7
V.PRECIPITATING / EXACERBATING FACTORS:
Factors Number  of cases Percentage
Sunlight
14 55%
Drugs
2 4.44%
Infections
5 11.11%
Mental stress
2 4.44%
Physical exertion 5 11.11%
Pregnancy
1 2.22%
Menstruation
2 4.44%
Others
1 2.22%
Sunlight was a  precipitating / exacerbating factor in 55% of cases. Cotrimoxazole and 
ibuprofen were the drugs which precipitated SLE   in each one patient. No exacerbating or 
precipitating factors seen in 26.66% patients.
VI. PRIMARY PRESENTATION:
Primary 
Presentation
with mucocutaneous 
problems only
with systemic 
problems only both
Number of patients 20 (45%) 18  (40.47%) 7 (14.53%)
Patients   primarily   presenting only with mucocutaneous   problems was seen in 45% of 
patients  and in patients    primarily  presenting with only systemic problems   was seen in 
40.47% and both in 14.53% of patients.
VII.  PATIENTS    PRIMARILY    PRESENTING    WITH  MUCOCUTANEOUS 
PROBLEMS ONLY:
Symptoms Number of cases Percentage
Photosensitivity               9         47.91%
Non scaring Alopecia               5         26.08%
Oral ulcer               4         21.73%
Urticaria               1          4.34%
Leg ulcer               1          4.34%
Photosensitivity  was  the  most  common  cutaneous   symptom  seen in  47.91% 
followed  by   diffuse  non scarring alopecia   in 26.08% and  oral ulcer  in 21.73% of  patients.
VIII: PATIENTS   PRIMARILY   PRESENTING   WITH   SYSTEMIC       PROBLEMS 
ONLY:
Symptoms Number  of  patients Percentage
Fever 8 45.45%
Arthralgia 6 35.71%
Oliguria 2 9.09%
Recurrent abortion 1 4.54%
Irregular menstruation 1 4.54%
           Fever  was  the  most  common   systemic  symptom  seen in 45.45% followed  by  
arthralgia  in  35.71%  of  patients.
IX. PHOTOSENSITIVITY   IN DIFFERENT SPECTRUM OF DISEASE:
Symptom CCLE SCLE ACLE
Photosensitivity 7 (41.17%) 3 (100%) 20 (80%)
Photosensitivity  was  seen  in  100%  of  patients  with  SCLE, 80%  of patients  with 
ACLE  and  41.17%  of  the  patients  with  ACLE.
X. CLINICAL   PRESENTATION DURING FOLLOW UP:
Follow up  duration
Patients initially presenting 
with cutaneous & later with 
systemic symptoms
Patients initially 
presenting with systemic 
symptoms & later with 
cutaneous symptoms
<6 months 7   (35%) 10   (55.55%)
6months -1yr. 8   (40%) 4    (22.20%)
1yr-1.5 yr. 3   (15%) 3    (16.55%)
1.5yr-2yrs 2 (10%) 1     (5.55%)
Among the patients  who initially  presented with cutaneous symptoms,  75% of them 
developed  systemic  symptoms  within  first  year  of  follow  up.  In    patients  who  initially 
presented with systemic symptoms 77.75% of them developed cutaneous symptoms with in 1 
year.
XI. ASSOCIATION OF SKIN LESIONS OF ARA CRITERIA WITH THE OTHER ARA 
CRITERIAS:
Skin   ARA   criterias
Other  ARA 
criterias
Malar 
rash
DLE 
lesions Photosensitivity
Oral 
ulcer
Arthritis 5 6 9 8
Renal criteria 1 1 2 2
Neuropsychiatric 
criteria 3 2 5 2
Hematological criteria 4 8 11 7
Immunological criteria 10 7 14 14
Photosensitivity was the most common ARA skin criteria associated with other ARA 
criterias followed by oral  ulcer and malar  rash.  Both photosensitivity  and oral  ulcers  were 
commonly associated with immunological criteria.
XII. DISTRIBUTION OF CUTANEOUS LESIONS:
Sites involved CCLE SCLE ACLE TOTAL
Only sun exposed area 3 - 5 6
Both sun exposed & non exposed 
area(disseminated) 3 3 3 10
Localised to head & neck 11 - 18 29
 Among the CCLE patients, 64.70% of the patients had localised DLE lesions, 35.30% of 
them had disseminated type. Among the SCLE patients all had disseminated lesions. Among 
the ACLE patients 72% had localised lesions and 28% had disseminated type.
XIII. MUCOSAL LESIONS:
Mucosa  involved CCLE SCLE ACLE Percentage
Palatal erosions or ulcers 4 2 13 83.30%
Erosions and crusting of lips 1 1 5 25%
Gingival erosions - - 1 3.57%
Conjuctiva - - 1 3.57%
Palatal involvement was the commonest in 83.30% of patients followed by erosions and 
crusting of lips. In patients with lip involvement vermilion border was blurred by crusting but 
the lesion did not extend beyond it. 
XIV.MORPHOLOGY AND SEQULAE OF LESIONS:
Among the CCLE patients 33.66% of the patients had classical plaque lesions of DLE, 
1.22% had verrucous DLE, and 1.22% had follicular plugging in the ears.  1.22% had LEP 
lesions, which was well defined, firm subcutaneous plaques that later ulcerated resulting in 
scarring. 60% of the patients with DLE lesions ended with depigmentation and scarring, 40% 
with hyperpigmentation and 15.55% with scarring alopecia.
   In patients with SCLE, 66% of them had classical papulosquamous lesions and 33% of 
them  had  annular  scaly  plaques.  These  annular  scaly  plaque  lesions  initially  started  as 
individual plaques which later, coalesced   to form large polycyclic scaly plaques. All SCLE 
lesions healed in due course without scarring.
 In ACLE patients with maculopapular rash, initially rash started in sun exposed area 
later on spread to whole of the body. Maculopapular rash, malar rash and butterfly rash were 
seen in 37%, 13.33% and 13.33% resp. Patient with bullous SLE had lesions throughout the 
body.
XV. INITIAL CLINICAL PRESENTATION:
LE specific skin lesions LE non specific 
skin lesions
Both
Total 
number of 
cases
CCLE SCLE ACLE
7
(30.43%)
4
(17.39%)5
(19.11%)
3
(13.04%
)
4
(17.39%
)
52.28% of  patients  presented  with  LE  specific  skin  lesions  as  initial  manifestation, 
30.43%  with  LE    non  specific  skin  lesions  as  initial  manifestation  and  both  as  initial 
manifestation in 17.39% patients. 
XVI. SPECTRUM OF LE SPECIFIC SKIN LESIONS:
LE specific skin lesions Number of patients Percentage
ACLE
Malar rash 17 68%
Butterfly rash 1 4%
Maculopapular rash 6 24%
Bullous lesions 1 4%
           
SCLE
Annular 1 33.33%
Papulosquamous 2 66.66%
Localised 11 64.70%
      CC
LE
Generalised 6 35.29%
Verrucous 1 5.88%
LEP 1 5.88%
Among    ACLE    patients,  malar  rash  was  commonly  seen  in  68%  followed  by 
maculopapular rash in 24%. In SCLE patients 66.66% had papulosquamous lesions, 33.33% 
had annular lesions. Among the CCLE lesions localised type is most commonly seen in 64.70% 
of patients followed by generalised type in 35.29%.
XVII. SPECTRUM OF LE NONSPECIFIC SKIN LESIONS:
Lesions Number of patients Percentage
Diffuse non scarring alopecia 22 48.88%
Nail changes 10 22.22%
Mucosal lesions 10 22.22%
Icthyosis 4 8.88%
Vasculitis
Urticarial vasculitis 2 4.44%
Purpura 2 4.44%
Leg ulcer 1 2.22%
Gangrene 1 2.22%
Acanthosis nigricans 2 4.44%
LE/ LP overlap 1 2.22%
Anetoderma 1 2.22%
Diffuse non scarring alopecia was the most common nonspecific skin lesion seen in 
48.88% followed by, nail changes in 22.22%, mucosal lesions in 22.22%. Among the patients 
with vasculitis 4.44% of them presented with urticarial lesions, 4.44% with purpura, 2.22% 
with leg ulcer and 2.22% with gangrene.  Icthyosis was seen in 8.88%, acanthosis nigricans in 
4.44% cases, and LE /LP overlap in 2.22% of patients. Other than the above said lesions 4.44% 
of the patients   had palmar exfoliation.
XVIII. ASSOCIATED SYSTEMIC MANIFESTATIONS:
Systemic  involvement Number  of patients Percentage
Fever 31 92.42%
Arthralgia 10 22.44%
Psychiatric 10 22.22%
Lupus nephritis 2 33.33%
Lymphadenopathy 5 11.11%
Respiratory system 4 8.88%
Neurological 2 4.44%
Conjunctivitis 1 2.22%
Fever was the most common symptom seen in 68.88% followed by musculoskeletal 
symptoms in 26.66% and psychiatric symptoms in 22.22%. 
XIX.HISTOPATHOLOGY:
Majority  of  our  study  patients  HPE  of  specific  lesions  showed  features  suggestive 
specific  for  LE.  Characteristic  LE  specific  skin  lesions  common  to  all  spectrum  like 
hyperkeratosis  was  seen  in  66.44%,  liquefaction  degeneration  of  basal  cells  in  100%, 
periappendageal   infiltrate in 34%, perivascular infiltrate in 28% of  patients .
In  patients  with  ACLE  various  other  HP features  other  than  the  common  features 
mentioned above  like sparse inflammatory infiltrate and upper dermal edema as documented in 
literature was seen in 56% and 16% resp. Extravasated RBC’s seen in 26% of patients. Patient  
with ACLE had bullous lesions which showed subepidermal bulla.
In  patients  with  SCLE  focal  liquefactive  degeneration  was  seen  in  66.66%,  sparse 
upper dermal infiltrate in 66.66% and upper dermal edema in 33.33%. 
 In  DLE patients   follicular  plugging was seen in  58%, keratotic  plugging in  51%, 
colloid bodies in 50%, dense and deep dermal infiltrate was seen in 51%, periappendageal 
infiltrate in 48% , more melanophages in 33%, perivascular infiltrate in 29% of patients. 
 Patients with urticarial vasculitis showed inflammatory infiltrate predominantly within 
and around small blood vessels mainly of neutrophils and also leukocytoclastosis. A case of 
LEP showed minimal atrophy of epidermis, inflammatory infiltrate cell collection in dermis 
and  septilobular  lymphohistiocytic  infiltrate  in  sub  cutis.  In  patient  with  LE/LP overlap, 
hypertrophic DLE lesions showed features of lichen planus, but ulcerative DLE lesions showed 
features of SCC, like individual cell keratinisation and keratin pearls.
XX. LABORATORY CRITERIA OF ARA IN VARIOUS SPECTRUMS OF SLE:
Lab criteria CCLE SCLE ACLE %
Anemia (Hb %<10gm/dl) 6 3 9 40%
Leucopenia (<4000/mm3) 1 2 4 15%
Thrombocytopenia(<1,00,000/mm3) - - 2 4.44%
 Lymphopenia(<1500/mm3) - - 4 15%
 Persistent Proteinuria - - 2 13.33%
24 hrs urine protein >150mg - - 2 33.33%
 ANA positivity 12 3 25 94%
dsDNA positivity 2 3 14 83%
False positive VDRL 1 1 4 18%
Immunofluorescence positivity - - 3 100%
Laboratory ARA criteria was fulfilled by most of the patients in ACLE spectrum. Two 
patients   confirmed to have lupus nephritis in biopsy. Abnormal levels of both IgG and IgM 
APL antibody was documented in 3 patients. SGOT and SGPT were deranged in 6 patients.  
ANA was positive in 100% of  SCLE patients, 70% of  CCLE patients and 100% of ACLE 
patients .
XXI. INDIRECT IMMUNOFLOURESCENT PATTERN:
TYPES/PATTERNS OF 
ANA NO OF PATIENTS
Homogenous 2
Speckled 1
All the 3 patient’s samples sent for Indirect IF and Direct IF were positive. In IDIF 2 of 
them showed homogenous pattern and 1 showed speckled pattern.
DISCUSSION
In this study, among the total 52,369 new patients attending skin op GGH, Chennai, 
during the study period of August 2007 to September 2009, total number of patients with SLE 
was 45. The incidence of SLE in our study is 0.08% as compared to incidence of 0 .01 to 
0.12% in literature27.  F.B.Yab et al100 study  showed an  incidence of 46.5%, 38.8%, 12.7%, and 
2% of ACLE, CCLE, SCLE, LEP respectively, which is comparable with our study  of 47.94%, 
39.92%, 8.48% and 2.86% of ACLE, CCLE, SCLE, LEP respectively. 
In Binoy.J.Paul et al101 study youngest and oldest patient seen were 16 years and 63 
years resp. In our study youngest patient documented was 15 years and oldest patient was 50  
years. In Binoy.J.Paul101and Malaviya et al102 studies average age was 21.6 years and 23 years 
resp. which is 22 years in our study. In Vaidhia et al103 and Masi et al104 studies 58% were 
between the age group of 20 to 30 years, but our study showed 62%. 
In Malaviya et al102 study female: male ratio is of 8:1 which is nearer to our study of 7:1. 
Burning sensation and erythema were the most common symptoms among   patients, which is 
63.63% & 42.42% respectively.  Photosensitivity  was the most common symptom in SCLE 
patients and pain is the most common symptom in LEP patient as documented in literature.27        
Sunlight,  infections,  drugs,  pregnancy,  menstruation,  stress  are  among  the  few well 
document precipitating (or) exacerbating factors that have been described in the literature27. 
Photosensitivity  was  observed in  52% in  Allkes  et  al105 study  done  in  PGI  and 54.4% in 
Nazarinia  et  al106 study,  which  is  comparable  with  our  study  of  55%.  Co-trimoxazole  and 
ibuprofen precipitated SLE in each one patient, which is also observed in literature. 27,28 Among 
the  45  patients,  26.66% of  patients  did not  relate  their  disease  with  any exacerbating (or) 
precipitating factors. Familial incidence of SLE has been reported but with rarity27,28.
 In our study, history of SLE was present in a patient’s sister, while another patient had 
an  elder  sister  with  Dermatomyositis.  One  patient  had  alopecia  and  another  had 
hypothyroidism. Rheumatoid arthritis was seen in one of the patient’s first degree relative. All 
these associations state a positive  correlation of  HLA association and autoimmunity in the 
pathogenesis of SLE28.
In Fung et al107 study, 44.52% presented only with mucocutaneous symptoms as primary 
complaints which is consistent with our study of 45%.  Binoy.J.Paul101 et al observed primary 
presenting complaints as photosensitivity in 78% of his study patients, non scarring alopecia in 
60%, malar rash in 57%, which is comparable with our study of 80%, 57.77% and 60% resp.
 Fung  et  al  107  showed  arthritis  as  primary  presenting  complaint  in  44%  while 
Binoy.J.Paul101 showed it as 66% which is comparatively high than our study of 34%. Fever 
was   primary presenting complaint in 56.6% of patients in Binoy.J.Paul101 study which is high 
compared to our study of 45.44%. Renal manifestations  as initial presentation were seen  6% , 
8%  and  7.4%  of  Ester  et  al108,  Malaviya  et  al102,  Radhamadavan  et  al109 study  groups 
respectively, but in our study group it was 9.09%. 
 Photosensitivity as a symptom is seen in 70% - 80% of ACLE patients, 60% -70% of 
SCLE patients and 40% of CCLE patients as per literature.27,28 In our study it was 88%, 100% 
and 43% of ACLE, SCLE and CCLE patients respectively.
Among the 20 patients who initially presented with mucocutaneous symptoms 75% of 
them developed systemic symptoms within one year and another 25% of them within next one 
year.  Among 18 patients  who presented with systemic symptoms initially,  77.75% of them 
developed cutaneous symptom within one year.  
Photosensitivity  is  the  most  common ARA skin  criteria  associated  with  other  ARA 
criteria as given in the literature27. Photosensitivity is most commonly associated with 36.65% 
of hematological criteria and 21.5% of immunological criteria.
In our study   distribution of the lesions were same as   described in the literature.28 In 16 
patients  with  DLE  73.64%  had  lesions  localised  to  the  head  and  neck,  26.46%  had 
disseminated type. This is compatible with the study of Millard and Rowell21. Binoy.J.Paul et al 
101 observed 18.17% had DLE lesions over the scalp which is nearer to our study of 17.7%. 
Involvement of the concha of the ear has been stressed as an important clue in the diagnosis of 
DLE by Rebra and Sam shuster67, in our study 17% patients had ear involvement. In SCLE, 
ACLE and LEP, lesions involved the classical sites as described in the literature27. 
Patients with ACLE, SCLE and CCLE had 43.21%, 28.62% and 28.17% of mucosal 
involvement resp. In our study majority of ACLE patients had mucosal  involvement followed 
by SCLE and ACLE as described in literature28.  Malaviya et al102documented oral involvement 
in 64% in his study as compared to 62% observed in our study. Among the mucosa, palate was  
involved in 83.30% of patients, lips in 25% and gingiva in 3.57%. Crusting of lips was the most 
common manifestation in patients, with lip involvement and characteristically spare vermillion 
border as described in the literature28.  
Morphology and sequelae of lesions were classical in the majority of the patients, in all 
the three spectrum as described in literature.27,28 In DLE patients majority of them had plaque 
like lesions which ended with scarring as described in literature.27 Few of the patients also had 
verrucous lesion, follicular plugging lesion in the ear which is also described in literature 27. In 
our study two third of SCLE patients had papulosquamous lesions and one third had annular 
lesions, both these types of lesions did not end in scarring   as described in the literature28. 
Vesiculation in active border seen in SCLE patients as in literature is not documented in our 
study.46 
In ACLE patients with maculopapular rash, initially rash started in sun exposed area 
later  on  spread to  whole  of  the  body.   In  our  study of  ACLE patients,  classical  lesion as 
described in litrature of ACLE patients like facial erythema, butterfly rash(sparing naso labial 
fold), generalised exanthematous rashes were described.28 LE/LP overlap turning in to SCC is 
seen in one patient, bullous lesion in one patient and LEP in one patient all of them had their 
morphology similar as described in literature27,28
As per Gilliam classification of specific and non specific lesions, specific skin lesions 
are  comparatively  common  than  non  specific  skin  lesions  in  our  study.  Kapadia  et  al110, 
Weysback et al111 and Vaidhiya et al  112who showed specific skin lesion in  55%, 53%, 50% 
respectively, which is  comparable to our study of 54.33%.  In Binoy.J.Paul et al101 study, malar 
rash was seen in 28%, butterfly rash was seen in 26% of patients and maculopapular rash was 
seen in 20%. In our study malar rash, butterfly rash and maculopapular rash were seen in 37%, 
35%, 18% respectively. Though only few presented with LE specific skin lesions initially, in 
due course of follow up, majority of them developed LE specific skin lesions.
Allkesh et al105 and F.B.Yab et al100 studies showed facial erythema in 80% and 86% 
respectively which is observed as 82% in our study. Out of 25 patients with ACLE 24% had 
butterfly rash, which is consistent with literature.27 Masi et al104 documented malar rash in 80% 
of patients which is observed as 76.52% in our study. Allkes et al105  observed bullous SLE in 
10% of their patients which is high compared to our study of 2.22%.
Zeevi et al113, Allkes et al103 showed diffuse non scarring alopecia in 86% and 85%  of 
patients respectively, which comparable to our study patients with 85%.  It was observed that 
the severity of hair loss was proportional to the disease activity, as also observed by Zeevi et  
al.113 Nail  changes were seen in 15% of patients  as compared to 25% in literatures.28 Nail 
changes documented in our study included ragged cuticle in 42%, paronychia in 25%, nail 
dystrophy in 16%, melanonychia in 6% and beau’s lines in 11%. The above nail changes were 
documented in the literature.28 In our study among the above findings ragged cuticle was seen 
in most of the patients.
Non specific mucosal lesions are seen in 26% of patients in literature28, but in our study 
it was 22.22%. In Allkes et al  105study vasculitis presented as urticaria in 10% of patients, as 
purpura in 8%, as leg ulcer in 10%, and as gangrene in10% of patients, but in our study it was 
4.44%, 4.44%, 2.22% and 2.22% respectively. Among the 2 patients with urticarial vasculitis 1 
patient had renal involvement and low complement levels which states that the urticaria may be 
due to immune complex mediation. Association of hypocomplementemia   was documented 
with lupus nephritis and urticaria in literature.27,28 Patients with leg ulcer, was also associated 
with urticarial vasculitis . LE/ LP over lap was seen in 1 patient, who turned into SCC later, 
which is a rare documentation in literature28.
Few other associated skin lesions were also seen in our study which includes icthyosis in 
8.88%,  acanthosis nigricans 4.44% and  anetoderma in 2.22% patients. The above findings 
though rare, are documented in literature27.
Associated  systemic  findings  were  most  commonly  seen  in  ACLE  patients  as  in 
literature.28 Allkes  et  al105 study  observed  fever  and  arthralgia  in  92.67%  and  22.4% 
respectively which is comparable with our study of 92.42% and 22.44%.  Binoy.J.Paul et al101 
and Malaviya et al102 studies observed lupus nephritis in 35% as compared to 33.33 % in our 
study.  Ester et al  108and Radha Madhavan et al  109studies showed renal symptoms as initial 
complaints in 6 & 7.4% respectively but in our study it was 4.04%.  
Respiratory problems were seen 26% in Nazarinia et al106  study which is comparatively 
higher than our study of 8.88%. Dubois et al115, Vaidiya et al  103  and Radhamadavan et al  109 
observed 25%  of  neuropsychiatric  manifestations in  their  patients  which is  nearer to our 
observation of 26.52%. Among 12 patients with neuropsychiatric manifestations 4.32% had 
seizures and 40% had psychiatric problems. Psychiatric manifestations included depression, 
anxiety neurosis and obsessive compulsive neurosis.  Lymphadenopathy was documented as 
50% in literature 28 but in our study it was11.11%. Conjunctivitis   observed in our study was a  
rare documentation in the literature.27
HPE DISCUSSION
Characteristic  HP skin  changes  of  LE  specific  skin  lesion  as  in  literature,27,28 like 
hyperkeratosis,  liquefaction  degeneration  of  basal  cells  periappendageal   infiltrate  , 
perivascular infiltrate is seen in  majority of patients. Varying mosaicism of these features are 
seen in 3 major spectrum of LE specific skin disease35.
It  is  described in literature28  that,  follicular plugging ,  keratotic plugging,  extensive 
basal cell degeneration, dense pigment incontinence, patchy inflammatory infiltrate  around and 
independent of appendages  and  dense deep dermal infiltrate is seen more commonly in DLE 
than in SCLE or ACLE35.The above finding is consistent with our study like extensive basal 
cell degeneration in 100%,  follicular plugging is seen in 74% of patients, keratotic plugging in 
65%,  dense  pigment  incontinence  in  82%,  dense  deep  dermal  in  filtrate  in  70%  and 
periappendageal  infiltrate in 68% of patients.
Focal liquefaction degeneration of basal cells, dermal edema and sparse inflammatory 
infiltrate in upper dermis (as against the deep dermal infiltrate of DLE lesions) which are all 
common documentation in SCLE patients in literature,  35  were also documented in our study. 
Other  uncommon  literature35 findings  like  atrophic  epidermis,  vesicular  changes  in  active 
borders, extravasation of RBC’s and fibrinoid deposits were not encountered in our study. 
As per literature35 reports  hyperkeratosis is less striking in ACLE  than  in DLE and 
SCLE, this finding is consistent with our study.125 Upper dermal sparse inflammatory cell,  and 
upper dermal edema, which is a common finding documented in literature35, was frequently 
encountered  in  our  study.  Focal  liquefactive  degeneration  which  is  a  common  finding  in 
literature,35 is seen  in  only few of our study patients. Histopathological feature of bullous SLE 
is consistent with the literature35. Severe forms of ACLE may have epidermal necrosis and the 
clinical lesion may resemble TEN.35 The above finding, which was a rare entity, has not been 
encountered in our study.
In patients with urticarial vasculitis histopathological examination showed inflammatory 
infiltrate predominantly within and around small blood vessels mainly of neutrophils and also 
leukocytoclastosis.  A  case  of  LEP  showed  minimal  atrophy  of  epidermis,  inflammatory 
infiltrate cell collection in dermis and septilobular  lymphohistiocytic  infiltrate  in  subcutis. In 
patient with LE/LP overlap, hypertrophic DLE lesions histopathologically showed features of 
lichen  planus,  but  ulcerative  DLE  lesions  showed  features  of  SCC  like,  individual  cell 
keratinisation and keratin pearls. All the above findings documented in our study were also 
seen in literature.35
LABORATORY FINDINGS
As reviewed in the literature28, most of the laboratory abnormalities have been attributed 
to the autoantibodies produced against the various components of different tissues. Binoj.J.Paul 
et al 101study showed   raised ESR in 65.43%, anemia in 42% and leucopenia in 13%   in his  
patients,  which  is  observed  as  63.34%,  42%,  and  15.55%  respectively  in  our  study. 
Thrombocytopenia was seen in 17.2% & 12.22% of Ester et al108 and Yokohari et al114 studies 
respectively, which is 4.45% in our study.  False positive VDRL was seen in 23% of Jarallah et  
al 112 patients, but in our study it was 18%.
In Allkes et al105 study 26.67% had abnormal 24 hrs urine protein excretion which is 
comparable to 33% in our study. Grade III lupus nephritis was observed in 49.7% of Nazarinia 
et al106 study as compared to our study of 50%. C3 and C4 levels were found low in 45% of 
patients in Arfaj et al 115study as compared to 66% of patients in our study. Rheumatoid factor 
was positive in 19% in Binoj.J.Paul101 et al study as compared to 11.11% in our study. All 6 
patients who had suspicion of antiphospholipid antibodies were investigated with IgG and IgM 
levels of APL.  50% among them   had abnormal levels which is same as that of Arfaj et al 
study115.
ANA was done for all the patients. Binoj.J.Paul et al  101and Nazarinia et al106 studies 
showed ANA positivity in of 93% and 94% respectively, which is almost correlating with our 
study of 94%. ANA positivity in literature28 in various spectrum like DLE, SCLE and CCLE 
are 30%-40%, 60% and 85% respectively. But in our study it was 70%, 100% and 100% in 
CCLE, SCLE and ACLE respectively. dsDNA was positive in 83% as also shown by Arfaj et al 
115and Nazarina et al.106 DIF and IDIF were done for 3 patients. All three patients specimen sent 
for lupus band test and IDIF, showed positive results. Two patients of IDIF positivity showed 
homogenous pattern and one patient showed speckled pattern. Patient with speckled pattern had 
lupus nephritis. Among the lab criterias of ARA, ANA was the most common criteria seen in 
94% of  patients,  followed by dsDNA in  83% of  patients,  anemia  in  40% of  patients  and 
leucopenia in 15% of patients.   Maximum lab criterias were fulfilled by patients  in ACLE 
spectrum as described in the literature.27,28 
SUMMARY & CONCLUSIONS
 The incidence of SLE during the period of August 2007 to September 2008 is 0.08%.
 ACLE is the commonest spectrum followed by CCLE and SCLE.
 Commonest age group falls between 20 to 30 years. Youngest age documented was 15 
years and oldest age was 50 years.
 Female preponderance was seen in all types of spectrum.
 Sunlight is the commonest among the precipitating and exacerbating factor followed 
by infections, physical/mental stress, drugs, pregnancy and menstruation.
 Familial  history  of  other  associated  autoimmune  disease  states  that,  genetic  back 
ground is an important contributing factor. 
 Diffuse hair loss and photosensitivity are common among the cutaneous symptoms. 
Palatal ulcer is the most common mucosal symptoms and it is commonly associated 
with ACLE. Fever and arthralgia are the most common symptoms among the systemic 
symptoms. 
 Among the patients who initially presented with cutaneous symptoms most of   them 
developed  systemic  symptoms  in  first  year  of  follow  up  likewise    patients  who 
initially  presented  with  systemic  symptoms majority  of  them developed cutaneous 
symptoms with in 1 year. 
 Among  the  clinical  skin  criterias  of  ARA,  photosensitivity  is  the  most  common 
criteria. Photosensitivity and malar rash are among the ARA skin criteria to have more 
correlation with other ARA criteria.
 Localised DLE is the most common type among the CCLE group. SCLE lesions are 
widespread and ACLE lesions are more commonly seen over the sun exposed area. 
  Among the specific lesions, malar rash and DLE are commonly encountered. Among 
the non specific skin lesions diffuse non scarring alopecia is the most common finding 
documented.
 Few  rare  observations  in  our  study  are  LEP,  bullous  SLE,  anetoderma,  urticarial 
vasculitis,  purpura, gangrene and acanthosis nigricans. LE/LP over lap turning into 
SCC, which is a rare entity, is encountered in our study. 
 ACLE spectrum is the commonest to be associated with systemic disease.
 Majority of the patient’s HP feature in various spectrum of SLE is consistent with that 
of literature. All the three patient’s samples sent for DIF and IDIF are positive.
 Maximum  laboratory  abnormalities  are  seen  in  ACLE  spectrum.  Among  the  lab 
criterias of ARA, Anemia, leucopenia and ANA positivity are the most common lab 
abnormalities observed.
PROFORMA
  
Case No Name Age 
RC No Sex 
Occupation Address Date 
Chief Complaints 
Cutaneous Extra Cutaneous. 
History of presenting illness 
Elaborate the symptoms 
Site Onset duration 
Progression regression 
PPT factors – 
           Photo sensitivity                  Food                                         Infections  
Stress       Mental      Physical 
Trauma       Drugs-Duration / name of drug 
Menstruation      pregnancy     Others 
H/O Constitutional symptoms 
H/O Implants 
H/O Raynaud’s phenomenon 
H/O heavy metal exposure – Type of metal – duration. 
H/O Shortening of fingers / ulceration 
H/O hair loss – re growth present / absent 
H/O urticaria 
H/O Purpura, nodules, papules
H/O Pigmentation, bullae 
H/O Oral ulcers 
H/O difficulty in swallowing 
H/O nasal symptoms 
History related to systemic involvement 
H/O Joint pain / deformity 
H/O suggestive of CVS movement 
H/O CNS involvement 
H/O Psychiatric disturbances 
H/O Respiratory tract involvement 
H/O Hematuria / loin pain 
H/O Ocular symptoms 
Past History 
Treatment History: 
Family history - Other family members affected 
- Any other connective issue disorder 
Personal - H/O abortion 
- H/O Premenstrual flare 
- H/O Perinatal mortality / Morbidity 
G/E anaemia jaundice clubbing lymphadenopathy 
BP HR RR Edema Built 
CVS - SIS2 /any other murmurs 
RS - NVBS / any added sounds 
Abd
CNS 
Joints 
Dermatological examination 
MORPHOLOGY – SKIN 
Erythema Malar rash Papule Patch 
Plaque atrophy scaling scarring 
Edema of face chronic ulcer telengiectasia urticaria 
Purpura Raynaud’s Icthyosis Discoid rash 
Bulla Pyoderma gangrenosum Acanthosis nigricans 
Follicular papules nodules Thrombophlebitis 
gangrene relapsing condritis  pigmentary abnormalities
Others
HAIR non scarring 
Alopecia lupus hair 
Scarring
NAIL splinter hemorrhage ragged cuticle red lunula
ridging onycholysis Others 
 
MUCOSA oral nasal 
Vulval perianal 
Others 
BLOOD 
HB% TC DC platelets 
ESR  
RFT
LFT
CRP VDRL HIV 
ANA                          ANA Pattern 
dsDNA                         Anti DNA antibody
Other Auto antibodies              Serum Complement levels 
RA factor                 ACL Antibodies 
Others 
URINE 
Albumin Sugar Deposits 
24 hrs urine protein excretion 
Skin biopsy 
Immunoflourescence          Indirect                              Direct 
ECG         ECHO
CXR        others 
Expert opinion 
REFERENCES
1. Talbott JH: Historical background of discoid and systemic lupus erythematosus 
in Lupus erythematosus, Ed. Dubois EL, Mc Graw Hill  Book Company,  New 
York and London, 1966:1-9
2. Walter J B and Israel M S: The Collagen diseases in General Pathology, ed. 
Walter JB and Israel M S Edn.5, Churchill, Livingstone Publications, Edinburgh, 
London and New York, 1979: 205.
3. Klemperer P: Concept of collagen diseases, Am J Path 1950; 26: 505.
4. Harvy M A, Shulman L E. Tumulty PC et al : Systemic lupus erythematosus: 
Review of literature and clinical analysis of 138 cases, Medicine, 1954; 33: 291-
437.
5. Ormsby OS and Montgomery H: Diseases of the skin, Edn.7, Lea and Febiger, 
Philadelphia, 1948 : 943-963.
6. Keil H: Conception of lupus erythematosus and its morphological variants with 
particular reference to systemic lupus erythematosus, Arch. Dermatol, 1937: 36: 
729-759
7. Burnham T K Neblett T R Fine G: The application of the fluorescent antibody 
technique to the investigation of lupus erythematosus and various dermatoses J 
Invest Dermatol, 1963; 41: 451-458.
8. Cohen,A  S,  Canoso  JJ:  Criteria  for  the  classification  of  systemic  lupus 
erythematosus- Status 1972, Arthritis Rheum 1972; 15: 540-543.
9. Tan  EM,  Cohen  A  S  ,  Fries  JF  et  al:  The  1982  revised  criteria  for  the 
classification of systemic lupus erythematosus, Arthritis Rheum, 1982; 25: 1271-
1277.
10. Rowell ,Lupus erythematosus, Scleroderma and Dermatomyositis in Text 
Book  of  Dermatology,  edn  Rook  A,  Wilkinson  DS and  Ebllng  FJG,  Edn.3  : 
Biackwell  Scientific  Publications,  Oxford,  London,  Edinburgh,  Boston 
Melbourne, 1979; 1151-1251.
11.Gilliam JN, Cohen SB, Sontheimer RD and Moschella SLs Connective tissue 
diseases in Dermatology, Edn Moschella SL and Hurley HJ, Ed 2, WB Saunders 
Company. Philadelphia, London, Mexico, New York, Sydney 1983; 445-467.
12. Lever WF and Lever GS: Connective tissue diseases. In Histopathology of 
the skin, Edn 6, JB Lippincott Co. London, Mexico, New York, Sydney 1983; 
445-467.
13. Rothfield NF: Lupus erythematosus In Dermatology in General Medicine, 
Eds Fitzpatrick TB, Eisen AZ, Wolff K Freedberg IM and Austen KF, Edn 2, Me 
Graw Hill Book Co. New York London, Mexico, Sydney, 1979J 1273-1296.
14. Dieppe  EPA,  Doherty,  M,  Macfarlane  DG  et  al:  Connective  tissue 
diseases, in Rheumatology Medicine Edn 2, Churchill Livingstone. Edinburgh, 
NewYork, London, Melbourne, 1985; 99-113.
15. Block SR, Lockshin MD,  Winfieid JB et alt Immunologic observation on 9 
sets of twins either concordant or discordant for SLE, Arthritis Rheum, 1976; 19: 
545-552.
16. Taurog JD and Steinberg AD: Genetic and Immune aspects of systemic 
lupus erythematosus, Int J Dermatol 1981; 20: 149-155.
17. Millard  L  0,  Rowell  WR  and  Rajah  SM:  Histocompatibility.  antigen  in 
discoid and systemic lupus erythematosus Br J Dermatol, 1977; 96: 139-144.
18. TNF alfa/Toll like receptors Fitz pattrik Textbook of Dermatology SEC .17; 
chapter  155 pg.1519-1526Ray TL:  Complement:  Practical  aspects,  Dermatol 
1983; 4: 525-534.
19. Gammon  WR:  Cutaneous  manifestations  of  Immunodeficiency,  in 
Dermatology, Edn Moschella SL and Hurley HJ Edn 2, WB Saunders company, 
Philadelphia, London, Toronto 1985;  225.
20. Byron AM and Hughes GRV: The connective tissue disease in  Oxford 
Textbook of Medicine. Eds. Weatherall DJ,.Ledln: Gham JGG and Warrell DA, 
Edn.1, Oxford University Press, Oxford Melbourne. Tokyo, 1984; 16.28 - 16.32.
21. Guyton, AC:  Pregnancy and lactation in Text Book of Medical Physiology. 
Ed 5, WB Saunders Company,  Philadelphia London Toronto Tokyo, 1976: 1110-
1111.
22. Van Uden JH Carson , Raze, Eur Jor Immun.2001 ;3281 -3290 kovics JG 
forking  hypothesis:  Viral  aetiology  of  autoimmune  disease,  New Eng J  Med 
1969; 280: 903-904.
23. Hashimoto K, Thompso DK and Memphi: Discoid lupus erythematosus, 
EM.  study of Paramyxo virus like structures. Arch Dermatol 1970; 101: 565-572.
24. Tuffanelli DL: Lupus erythematosus, Arch Dermatol 1972;106: 553-566.
25. Kovics JG forking hypothesis: Viral aetiology of autoimmune disease, New 
Eng J Med 1969; 280: 903-904.
26. Williams OG and Peters DK: Glomerulonephritis and renal manifestations 
of  systemic  disease  in  Oxford  Textbook  of  Medicine,  Eds.  Weatherall  DJ, 
Ledingham JQG and Warrell Da,  Oxford University Press,  Oxford, Melbourne 
Tokyo, 1984; 18.45 to 18.46.
27. ROOK  Textbook of dermatology  volume3,chap.56 page 1-127
28.  Fitz pattrik Text book of Dermatology  volume1,chap 156  page 1424-
1568
29.  Marrack .p.,Kappler .j .w  Jor. Infection ;1990’248;705-711.
30. Dustan HP; Taylor RD, Corcoran AC and Page IH: Rheumatic and febrile 
syndrome during prolonged hydralazine therapy, JAMA 1954; 154: 23-29.
31. Harmon EC; Portanova PV: Drug induced lupus in Clin. Rheum Dis 1982, 
8:  121-135.
32. Kammer .G.M. Stein ,Jor. immune dysfunction in SLE ;190;115;273-282
33. Veda .y. Sakane .t, BGF in SLE Jor. Immu. 1989;143;3988-3993.
34. Emlen .w., Kadeeva .r. Jor. Iimmu 1984;154; 3685-9.
35. George .j. Shoenfeld, Lupus jor. Idiotypes is SLE 1995;;4;333-335
36. Hudson  –Peacock  .M.G  ,Joseph  .s.a,  complements  in  SLE  .  bjd-
1997;136;388-392.
37. Pascual  .v.,palucka  .ak.  current   jor.  in  Rheumatology   Role  of  DC’S 
2003;548.
38. Jarett A:  The collagenoses,  in The Physiology and Pathophysiology of 
skin, Ed Jamett, A. Academic Press, London 19 : Vol.3 950.
39. Romero  RW,  Nesbitt  LT  and  Reed  R:  Unusual  variant  of  lupus 
erythematosus or lichen planus. Arch Dermatol, 1977; 113: 741-748.
40. Ropes  M:  Observations  on  the  natural  course  of  disseminated  lupus 
erythematosus, Medicine, 1964; 43:387-391.
41. Clough JD,  Elrazack  M,  Calabrese LH et  alt  Weighted  criteria  for  the 
diagnosis of systemic lupus erythematosus, Arch Int Ned 1984?  144s 281-285.
42. Dubois EL and Mart el S: discoid lupus erythematosus -An analysis of its 
systemic manifestations, Ann Int Medicine 1956; 44: 482-496
43. Izumi A and Takiguchi P: Lupus erythematosus Panniculitis Arch Dermatol 
1983,  119: .61 
44. Mi Hard LG and Kowell NRt Chilblain lupus erythenatoaus, a clinical and 
lab.  study of 17 patients, Br J Dermatol 1978, 98: 497-506.
45. Vitto J, Santa Cruz DJ, Eisen &Z et als Verrucous lesions in patients with 
DIE - Clinical histopathological and immunoflourescent studies, Br J Dermatol. 
1978, 98J 507- 520.
46. Camisac, Neff JC and Oslen RGZ Use of indirect immune florescence in 
the  LE/LP  overlap  syndrome:  An  additional  diagnostic  clue,  J  Am  Acad. 
Dermatol, 1984; 11:  1050-1059.
47. Rothfield N:  Clinical  features of  systemic lupus erythematosus in Text 
Book of Rheumatology, Eds. Kelly WN, Harris ED, Ruddy S and Sledge CB, 
Ed.2, WB Saunders Company, Philadelphia, London, Toronto 1985; 1070-1095.
48. Vonderheid  EC,  Koblenaer,  PJ,  Ming  PML  et  alt  Neonatal  lupus 
erythematosus. Report of four cases with review of the literature, Arch Dermatol 
1976; 112: 698-705.
49. Pandhi PK, Gupta R, Kumar AS.  et al Discoid lupus erythematosus in 
Northern India,  Ind J. Dermatol Venereal Leprol,1984; 50: 97-100.
50. Millard  LG  and  Lowell  NR:  Abnormal  laboratory  test  results  and  their 
relationship to prognosis in Discoid IUPUS erythematosus (A long term follow up 
of 92 patients).Arch Dermatol 1979,  115: 1055-1058.
51. Braverman IM: Skin signs of systemic diseases, Ed. 2,WB. Saunders Company, 
Philadelphia, London, Toronto 1981; 255-299.
52. Domonkos  AN,  Arnold  HL and  Odom:  Connective  tissue  diseases,  in 
Andrews'  Diseases  of  the  skin,  Ed.  WB Sounders  Company,   Philadelphia, 
London, Toronto, 1982;
53. Naeemann T, Saurbrey W and Burgdorf WHC: Connective tissue disorders 
in fundamentals  of  Dermatology,  Spring Verlag,  Newyork,  Heidelberg,  Berlin, 
1983; 169-170.
54. William  JN and  Sontheimer  RD:  Skin  manifestations  of  systemic  lupus 
erythematosus, Clin Rheum. Dis. 1982 8: 207-218.
55. Prystowsky  SD  and Gilliam JN: Cutaneous subsets  of  lupus erythematosus, 
Dermatol Clin 1933; 4: 449-459.
56. Thiers BH:  Anniculitis, Dermatol Clin 1983; 4, 548.
57. Lever  WF and  Lever  G5:  The  overlap  syndrome  lichen  planus/  lupus 
erythematosus, in Histopathology of the skin, Edn: 6, JB Lippincott Company, 
London, Mexico, Newyork, Sydney, 1983; 152.
58. Rebra:  Scarring of  the concha as a sign of  lupus erythematosus.  Br J 
Dermatol 1982; 106: 122.
59. Samsushter: A simple sign of discoid lupus erythematosus, Br J Dermatol, 
1981; 104: 349.
60. Roundtree J, Weigand D and Burgdorf Wit Lupus erjfythematosus with oral and 
perianal mucous membrane lesions. Arch Dermatol 1982; 118: 55-56.
61. Dabski  K,  Stoll  Hljrj  Cutaneous  horn  arising  in  chronic  discoid  lupus 
erythematosus, Arch Dermatol, 1985; 121: 837-838 (Letter to Editor).
62. Ueki  H,  Takei  Y and Nakagawa  S: Calcinosis  cuits  in  locali  sed  DLE,  Arch 
Dermatol, 1980; 116: 196-197.
63. Thurston CS, Curtis AC and Arbor A: Lupus erythematosus, Profundus (Kaposi 
Irgang): Clinical response to hydroxychloroquine sulphate. Arch Dermatol 1966, 
93: 577-582.
64. Arnold HL Jr: Lupus erythematosus profundus, Arch Dermatol, 1956; 73: 
15-33.
65. Sngelhart JJ: Drug induced lupus erythematosus profundus (Kaposi-Irgang) Br J 
Dermatol, 1982; 196:607.
66. Zehgel VN, Rege VL and VaciraJ 3N: An unusual cutaneous manifestation of 
systemic lupus erythematosus, Arch Der matol 1971; 103: 4o3-464.
67. Sontheimer RD, Thomas JR and Gilliam JN: 3ubacute cutaneous lupus 
erythematosus - A cutaneous marker for a distinct LE subset, Arch Dermatol, 
1979; 115: 1409-1415.
68. Tromovitch  TA  and  Hyman  AB:  systemic  lupus  erythematosus  with 
haemorrhagic  bullae.  a  case  with  LE  cell  recovered  from  the  bullae,  Arch 
Dermatol 1961; 83: 910-914.
69. Murray  JC:  Miscellaneous  blistering  diseases  in  Dermatol.  Clin,  1983; 
315-316.
70. Tuffanelll DL and Dubols EL: Cutaneous manifestations of systemic lupus 
erythematosus Arch Dermatol 1964; 90: 377-386.
71. Morelli  J.G La.Ro positive neonatal LUPUS Jor. Of AMERICAN academy OF 
dermatologist 1990;40;675-81
72. Caputo RVs Recent advances in Paediatric  Dermatology in Paed. Clin 
North America, 1983; 30: 739-741.
73. Jackson  R  and  Gulliver  M:  Neonatal  LE:   Progresses  to  SLE,  Br  J 
Dermatol,  1979; 101:81.
74. Black C: Mixed connective tissue disease Br J Dermatol, 1981;  104: 713-
719.
75. Gilliam  JN  and  Prystowsky  SD:  Mixed  connective  tissue  disease,  in 
Dermatology Update, edn Moschella SL, Elsevier, Newyork, 1979; 173.
76. Gilliam  JN  and  Prystowsky  3D:   Conversion  of  discoid  lupus 
erythematosus to Mixed connective tissue disease, Rheumatol, 1977; 4: 165-
169.
77. Bean SF and Lynch FW: Senear Usher syndrome, Arch Dermatol, 1971; 
101: 642-645.
78. Chorzelski  T,  Jablonska  S  and  Bhszczyk  M:  Immunopathology  in  the 
Senear Usher Syndrome  (Co-existence of Pemphigus and LE), Br J Dermatol 
1968,  80: 211-217.
79. Mannik M and Gilliland BC: Systemic lupus erythematosus inHarrison's 
Principles of Internal Medicine Eds.  Peters- Dorf RG, Adams RD. Brawnwald E, 
et al Ed. 10, Mcgraw Hill Book Co. New York, 1923; 387-391.
80. Clark  WH,  Reed  R.J  and  Miln,  N:   LE:  Histopathology  of  cutaneous 
lesions, Human Pathol 1973; 4:  157-163.
81. O'Loughlias,  Schroeter AL and Jordon RE: A study of LE with particular 
reference to generalised discoid lupus, Br J Dermatol 1978; 99: 1-11.
82. Callen JP: Chronic cutaneous lupus erythematosus, Arch Dermatol, 1982; 
118: 412-416.
83. Esters D and Christian CL:  The natural history of systemic lupus erythematosus 
by prospective analysis Medicine. 1971? 50:85-95.
84. Milner  ANP:  Systemic  lupus  erythematosus  with  nodular  lesions,  Br  J 
Dermatol, 1953; 65: 204-211.
85. Callen JP and Lowrsville: Systemic lupus erythematosus in patients with chronic 
cutaneous  (discoid)LB:  Clinical  and laboratory  findings  in  17  patients,  J  AM 
Acad Dermatol, 1985; 12: 278-288.
86. Prunieras M and Montgomery H: Histopathology of cutaneous lesions in 
systemic lupus erythematosus Arch Dermatol, 1956, 74: 177-189.
87. Bangert,  JL,  Freeman  HG,  Sontheimer  RD  et  alt  Subacute  cutaneous 
lupus  erythematosus  and  Discoid  lupus  erythematosus:  Comparative 
histopathologic findings Arch Dermatol, 1984; 120: 332-337.
88. Hood AF, Kwan TH, Burnes DC et al: Primer of Dermatopathology. Little 
Brown and Company, Boston, Toronto,1984; 161.
89. Ackerman  BA,  Niven  J,  Grant  Keli:  differential  diagnosis  In 
Dermatopathology, Lea and Febiger Philadelphia 1982;38-42.
90. Lever, WF and Lever GS: Non infectious erythematosus. 
91. Monroe EW; Lupus band test, Arch Dermatol 1977: 113t 830-834.
92. Jordon RE: Cutaneous immunoflourescence, Clin Rheum Dis 1982; 8: 479-
491.
93. Dahl MV: Usefulness of Direct Immunoflourescence in patients with lupus 
erythematosus Arch Dermatol, 1983;  119: 1010-1017.
94. Miller.m.h,Urowitz .m.b,Gladman JOR. rheu.;1998;15;1012-1013.
95. Derksen, Stephen APL a multisystem intergral approach 1995; 34; 567; 569
96. Ting .w.wSontheimer .Therapy for SLE; Lupus JOR.2001;171
97. Rowell NR: discoid lupus erythematosus, In current Dermatologic therapy, 
Ed. Maddin S Ed.2 : B Saunders ompany, Philadelphia, London Sydney, 1982; 
133-135.
98. Khop J, Happle R, Bonsmann G et al: Treatment of chronic discoid lupus 
erythematosus with Thalidomide. Year Book of Dermatol, 1982; 174-175.
99. Ruzlcka T and Goerz Gi Dapsone in the treatment of lupus erythematosus 
Br J Dermatol 1981; 104: 53-56.
    100. F.B.Yab et al IJDVL,yr.2009,Volume 75, issue-3,pg. 203
    101. Binoy .J.Paul et al J. Rheum.Ass.,2003, 11:94-97
    102. Malaviya et al Lupus Jr.,vol 6,no. 9, 690-700(1997)
    103. Vaidhiya et al SLE review JIRA, 1997; 5:14-18
    104. Masi AT, Kaslow RA. Sex effects in SLE – a clue to pathogenesis.  
Arthritis Rheum 1978;21:480.
    105. Alakesh IJD,YR. 2009, vol-75, issue 3, pg 203
    106. Nazzarinia et all Lupus Jr.,vol 8,no. 21,1690-16903 (1997)
107. Feng PH, Boey ML. Systemic lupus erythematosus in Chinese The  
Singapore Experience. Rheumatology Int 1982;2:151-4.
    108. Ester et al. Lupus erythematosus Arch Fr Pediatr 1989;46:601-4.
109. Radha Madhavan et al. SLE – The Madras Experience. J Assoc 
        Phys India 1988; 36:481-484.
    110. Kapadia et al, Lupus Jr.,vol 54,issue. 2,132-136 (2009)
    111. Wesback et al ,Lupus Jr.,vol 7,issue.26,132-136 (2001)
    112. Jarrhallah, Lupus Jr.,vol 3,issue.7,142-143 (1994)
    113. Zeevi et al SLE review JIRA, 1993; 5:123-126
    114. Yokohari R, Tsunematsu T. Application to Japanese patients,  of  the  1982 
American  Rheumatism Association  revised criteria for  the classification of 
systemic lupus erythematosus.Arthritis Rheum 1985;28:693-8.
KEY TO MASTER CHART
M : Male
F : Female
ppt : Precipitating factor
agg : Aggravating factors
ESR : Erythrocyte sedimentation rate
Drg : Drugs
D : Disseminated
L : Localised
sun : Sunlight
ps : Physical stress
MS : Mental stress
pmf : Premenstrual flare
INF : Infections
alc : Alcohol
preg : Pregnancy
pneu : Pneumonia
LN : Lupus nephritis
NP : Neuropsychiatric
conj : Conjuctiva
pal : Palate
UV : Urticarial Vasculitis
pur : Purpura
NSA : Non scarring alopecia
SA : Scarring alopecia
Nc : Nail changes
AN : Acanthosis nigricans
gang : Gangrene
ANE : Anetoderma
ANU : Annular
PSq : Papulosquamous
Lu : Leg ulcer
Ic : Icthyosis
ABBREVIATIONS
SLE : Systemic Lupus Erythematosus
DLE : Discoid Lupus Erythematosus
SCLE : Subacute Cutaneous Lupus Erythematosus
ACLE : Acute Cutaneous Lupus Erythematosus
DDLE : Disseminated Discoid Lupus Erythematosus
DIF : Direct Immuno Fluorescence
IDIF : InDirect Immuno Fluorescence
LE/LP : Lupus Erythematosus/ Lichen Planus overlap
LEP : Lupus Erythematosus Panniculitis
TNF : Tumour Necrosis Factor
INF : Interferon
dsDNA : Double Stranded DNA
ENA : Extractable Nuclear Antigen
LBT : Lupus Band Test
DEJ : Dermo Epidermal Junction
BMZ : Basement Membrane Zone
Ig : Immunoglobulin
EMF : Erythema Multi Form

